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HEAT SHOCK PROTEIN 90, A POTENTIAL BIOMARKER FOR TYPE I DIABETES: 
MECHANISMS OF RELEASE FROM PANCREATIC BETA CELLS 
 
Heat shock protein (HSP) 90 is a molecular chaperone that regulates diverse 
cellular processes by facilitating activities of various protein clients. Recent studies have 
shown serum levels of the alpha cytoplasmic HSP90 isoform are elevated in newly 
diagnosed type I diabetic patients, thus distinguishing this protein as a potential 
biomarker for pre-clinical type I diabetes mellitus (TIDM). This phase of disease is known 
to be associated with various forms of beta cell stress, including endoplasmic reticulum 
stress, insulitis, and hyperglycemia. Therefore, to test the hypothesis that HSP90 is 
released by these cells in response to stress, human pancreatic beta cells were 
subjected to various forms of stress in vitro. Beta cells released HSP90 in response to 
stimulation with a combination of cytokines that included IL-1β, TNF-α, and IFN-γ, as 
well as an agonist of toll-like receptor 3. HSP90 release was not found to result from 
cellular increases in HSP90AA1 gene or HSP90 protein expression levels. Rather, cell 
stress and ensuing cytotoxicity mediated by c-Jun N-terminal kinase (JNK) appeared to 
play a role in HSP90 release. Beta cell HSP90 release was attenuated by pre-treatment 
with tauroursodeoxycholic acid (TUDCA), which has been shown previously to protect 
beta cells against JNK-mediated, cytokine-induced apoptosis. Experiments here 
confirmed TUDCA reduced beta cell JNK phosphorylation in response to cytokine stress. 
Furthermore pharmacological inhibition and siRNA-mediated knockdown of JNK in beta 
cells also attenuated HSP90 release in response to cytokine stress. Pharmacological 
inhibition of HSP90 chaperone function exacerbated islet cell stress during the 
development of TIDM in vivo; however, it did not affect the overall incidence of disease. 
viii 
Together, these data suggest extracellular HSP90 could serve as a biomarker for pre-
clinical TIDM. This knowledge may be clinically relevant in optimizing treatments aimed 
at restoring beta cell mass. The goal of such treatments would be to halt the progression 
of at-risk patients to insulin dependence and lifelong TIDM. 
 
Janice S. Blum, Ph.D., Chair 
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INTRODUCTION 
I. Overview of the Immune System 
 The human immune system has evolved a number of intricate mechanisms over 
the millennia to protect our species from infection with pathogenic microorganisms. 
Certain components of the immune system are also involved in healing tissue damage 
induced by these infectious agents as well as other environmental insults. Our immune 
systems can even target and kill cancerous cells. In order to recognize an invading 
pathogen, the immune system must have the ability to distinguish self from non-self. To 
be fully protective, the immune system must also be able to differentiate benign 
substances in our environment from those that are harmful, as well as healthy cells from 
those that are malignant. The immune system is traditionally thought to orchestrate 
these processes through two distinct branches: the innate immune system and the 
adaptive immune system (1). 
II. Innate Immune Mechanisms 
 The innate immune system is the human body’s first line of defense against 
pathogen invasion. It serves to prevent pathogen entry or to detect and destroy an 
invading microorganism within minutes or hours of its breach. The body’s epithelial 
surfaces act as barriers that prevent pathogens from entering and establishing an 
infection. If a pathogenic organism does manage to break through these barriers, other 
innate mechanisms are standing by to prevent propagation of the pathogen throughout 
the host. 
A. Phagocytes  
Phagocytes are specialized immune cells that recognize and engulf, or 
phagocytose, infectious microorganisms. These cells also ingest debris and dead cells 
to promote tissue repair and wound healing. Phagocytic cells include neutrophils, the 
short-lived first responders to a site of infection; macrophages, long-lived tissue-resident 
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phagocytes that mature from circulating monocytes; and dendritic cells, central players 
in both activation of adaptive immunity as well as antiviral responses.  
During infection, pathogens are destroyed when the phagosome, the vacuole 
containing the phagocytosed microorganism, fuses with a lysosome, thus forming the 
phagolysosome. Within the phagolysosome, pathogens are destroyed through the 
production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). 
Neutrophils and macrophages produce high levels of ROS and RNS that potently 
degrade bacterial proteins. Dendritic cells, on the other hand, produce lower levels of 
ROS and RNS and are therefore better at preserving certain specific epitopes, or 
antigenic determinants, of bacterial proteins. This feature is essential for later activation 
of the adaptive immune system (1). 
 An important feature of phagocytic cells that allows them to distinguish self from 
non-self is the expression of pattern recognition receptors (PRRs). These receptors 
recognize conserved features of microorganisms known as pathogen-associated 
molecular patterns (PAMPs). These are features unique to microorganisms and are not 
present on host cells.  
B. Toll-Like Receptors 
 One important family of PRRs is the Toll-like receptor (TLR) family. These 
receptors are thus named because they are homologs of the Drosophila melanogaster 
Toll receptor. This receptor is important for innate immune responses to fungal 
pathogens in fruit flies. Thus, TLRs represent an ancient, evolutionarily conserved 
pathogen-recognition system (1). Humans express several TLRs that recognize PAMPs 
from various types of pathogenic organisms: gram-positive and gram-negative bacteria, 
mycobacteria, fungi, and viruses. For example, TLR3 recognizes double-stranded (ds) 
ribonucleic acid (RNA) encoded by viruses; TLR4 recognizes lipopolysaccharide (LPS), 
a component of the outer membrane of gram-negative bacteria; and TLR9 recognizes 
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deoxyribonucleic acid (DNA) with unmethylated CpG, a PAMP expressed by intracellular 
bacteria and herpesviruses. TLRs are expressed in distinct cellular locations depending 
on where the pathogenic organism is likely to be found. For example, TLR3 is generally 
located on endosomal membranes to facilitate the encounter of this TLR with viruses, 
given these intracellular pathogens often infect cells via delivery into the endocytic 
pathway. On the other hand, TLR4 is most often located on the plasma membrane 
because gram-negative bacteria are extracellular pathogens (2). 
 Cell signaling via TLRs induces expression of cytokines, chemokines, 
antimicrobial peptides, and type I interferons (IFNs) that normally promote inflammation 
and pathogen clearance. However, signaling through TLRs can also induce expression 
of anti-inflammatory cytokines such as interleukin (IL)-10 to counterbalance strong pro-
inflammatory responses that could result in tissue damage. These genes are induced in 
response to a number of signaling pathways that each results in the activation of 
different transcription factors. 
One important transcription factor family activated by TLR signaling is the nuclear 
factor κ-light-chain-enhancer of activated B cells (NF-κB) family of transcription factors. 
TLR signaling can also activate members of the activator protein-1 (AP-1) family through 
signaling pathways involving mitogen-activated protein kinases (MAPKs). Furthermore 
TLR signaling can activate members of the interferon regulatory factor (IRF) family. NF-
κB and AP-1 both induce expression of pro-inflammatory cytokines and chemokines, 
while the IRF transcription factors induce expression of the antiviral type-I IFNs, IFN-α 
and IFN-β (2).  
Pro-inflammatory cytokines secreted in response to PRR engagement include IL-
1β, tumor necrosis factor (TNF)-α, and IL-6. Pro-inflammatory cytokines promote 
changes in blood circulation that allow serum proteins and immune cells to access the 
site of microbial invasion in order to clear an infection and prevent its dissemination 
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throughout the body. This process is commonly known as an inflammatory response. 
Additionally PRR engagement can promote IFN responses (1). 
C. Pro-Inflammatory Cytokines 
IL-1β is largely produced by neutrophils and macrophages but can also be 
produced by epithelial cells, endothelial cells, and fibroblasts. Mature IL-1β is secreted 
through an unconventional protein secretion pathway in response to inflammasome 
activation. Once secreted, this cytokine can act in a paracrine or systemic fashion. IL-1β 
signals through the ubiquitously expressed type 1 IL-1 receptor (IL-1R1) on target cells, 
resulting in the activation of NF-κB transcriptional activity as well as the c-Jun N-terminal 
kinase (JNK) and p38 MAPK signaling pathways, which activate the AP-1 and cAMP 
response element binding (CREB) transcription factors, respectively. Together these 
signals induce expression of canonical IL-1 target genes such as IL6. 
Interestingly, many components of the IL-1 signaling pathway are also part of 
TLR signaling and other signaling cascades induced by cytotoxic stressors (Figure 1) 
(3). IL-1β activates the local vascular endothelium and increases access of effector 
immune cells to the site of infection. Specifically, it is a potent chemoattractant for 
neutrophils. These processes allow the pathogen to be cleared before it can spread to 
other parts of the body. However, IL-1β also results in fever and can promote local tissue 
destruction (1). 
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expressed in the majority of tissues. Similarly to IL-1β, TNF-α signaling also results in 
the activation of NF-κB transcriptional activity as well as the JNK and p38 MAPK 
signaling pathways; however, TNF-α is also known to induce apoptosis in some 
situations (Figure 1) (4). TNF-α activates the vascular endothelium, induces local 
vasodilation, and also stimulates endothelial cells to express factors that promote blood 
clotting and occlusion of local small blood vessels. This activity of TNF-α is important for 
preventing the dissemination of a pathogen throughout the body. However, if bacteria 
are present in the bloodstream, a condition known as septicemia results, during which 
macrophages release massive amounts of TNF-α, causing systemic vasodilation. This 
vasodilation leads to a dramatic drop blood pressure and a life-threatening condition 
known as septic shock (1). 
IL-6 is produced by macrophages, dendritic cells, B cells, keratinocytes, 
fibroblasts, and epithelial cells, among other cell types, in response to stimuli such as 
LPS, IL-1β, and TNF-α. It binds to the specific IL-6 receptor expressed on target cells 
which utilizes the common signaling component gp130 to initiate signaling through the 
Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. The 
IL-6 receptor is highly expressed by leukocytes and hepatocytes. In the development of 
an adaptive immune response, IL-6 signaling can promote the development of T helper 
(Th)17 cells over T regulatory (Treg) cells. It also is extremely important for plasma B 
cell differentiation (5).  
As part of the innate immune response, the cytokines IL-1β, TNF-α, and IL-6 
cooperatively activate hepatocyte production of acute-phase proteins. Acute-phase 
proteins coat the surface of, or opsonize, pathogens, which promotes their clearance by 
phagocytes. They also stimulate the release of neutrophils from bone marrow, further 
promoting pathogen clearance. IL-1β, TNF-α, and IL-6 are also endogenous pyrogens, 
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meaning they act on the hypothalamus to elevate body temperature, which also 
facilitates pathogen clearance (1). 
D. Interferon Responses 
Type I IFNs include IFN-α, a family of several closely-related proteins, and IFN-β. 
These cytokines, first identified for their ability to “interfere” with viral replication, are 
produced largely in response to viral infection, but can also be produced in response to 
infection with certain types of bacteria (6). Practically all cell types can produce these 
cytokines, but plasmacytoid dendritic cells are particularly specialized for this function. 
Once released, these cytokines bind to the type I IFNα/β receptor, expressed by a 
number of cell types, and initiate signaling via the JAK-STAT pathway. Type I IFN 
signaling induces the expression of genes encoding antiviral proteins and also 
upregulates expression of genes involved in the major histocompatibility complex (MHC) 
class I pathway, which is important for the initiation of adaptive immune responses. In 
addition to activating macrophages and dendritic cells, type I IFNs activate natural killer 
(NK) cells to kill virus-infected cells and induce the expression chemokines that recruit 
lymphocytes to the site of infection. All of these activities of type I IFNs help induce a 
cellular state in which viral replication is inhibited (1). 
IFN-γ is the only member of the type II class of IFNs. During innate immune 
responses, it is produced by monocytes, macrophages, dendritic cells, and NK cells. 
During adaptive immune responses, it is secreted by CD4+ Th1 cells as well as CD8+ T 
cells. IFN-γ binds the IFN-γ receptor, which is expressed by numerous types of immune 
cells as well as non-immune cells, and activates signaling primarily through the JAK-
STAT pathway. Once activated, STAT1 homodimers translocate to the nucleus and bind 
to promoter sequences containing an IFN-γ activation site. Several IFN-regulated genes 
are themselves transcription factors, such as IRF-1, that help promote the next wave of 
transcriptional changes. IRF-1 target genes include NOS2, which encodes the inducible 
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nitric oxide synthase (iNOS), and IFNB1, which encodes IFN-β. IFN-γ also upregulates 
genes involved in the MHC-I and MHC-II antigen presentation pathways and the 
development of Th1 cell responses, both of which are important elements of the 
adaptive immune response. IFN-γ also inhibits cell proliferation, regulates apoptosis, and 
activates the microbicidal effector functions of macrophages and other cell types. 
Similarly to type I IFNs, IFN-γ is also important for the induction and maintenance of an 
antiviral state (7). 
The innate immune system offers several elegant mechanisms to help clear 
infections with pathogenic microorganisms and promote wound healing. However, the 
innate immune system lacks a vast diversity of highly-specific antigen receptors and the 
ability to form cellular memory, two features that are required for an optimal immune 
response. These elements are hallmarks of the adaptive immune system. 
III. Adaptive Immune Mechanisms 
 The adaptive branch of the immune system is further divided into two 
components: cellular immunity, which is mediated by CD4+ Th cells and CD8+ cytotoxic 
T cells working in concert with certain myeloid cells, and humoral immunity, which is 
mediated by B lymphocytes and the antibodies they secrete. 
 To initiate an adaptive immune response, antigen presenting cells (APCs), of 
which dendritic cells are the most potent activators of naïve T cells, acquire antigenic 
proteins derived from the invading microorganism. These proteins are then processed 
into smaller peptide fragments and presented on the cell surface to naïve T cells in the 
context of MHC-I or MHC-II molecules. CD4+ T cells recognize antigen presented in the 
context of MHC-II (Figure 2), while CD8+ T cells recognize antigen presented in the 
context of MHC-I (8). To be activated, the antigen-specific T cell receptor of a naïve T 
cell must recognize its specific epitope presented in the context of the correct MHC in 
the presence of co-stimulation (9). 
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macrophage activation and the clearance of viral infections as well as infections with 
other intracellular pathogens. During this process, CD4+ T cells can also differentiate into 
either central memory or effector memory CD4+ T cells (10). 
B. Cytotoxic CD8+ T Cell Responses 
 During the course of an infection, CD8+ T cells are activated by APCs in the 
lymph nodes and spleen, sometimes with the help of CD4+ T cells, depending on the 
pathogen (11). Cytotoxic CD8+ T cells then undergo clonal expansion and migrate to 
peripheral tissues where they recognize infected cells that present antigen in the context 
of MHC-I and subsequently induce apoptosis of these infected cells (12). CD8+ T cell-
mediated induction of apoptosis may be achieved by the delivery of perforin and 
granzyme to the target cells or by engaging death receptors such as FAS expressed on 
the target cell surface (11; 12). Similarly to effector CD4+ T cells, cytotoxic CD8+ T cells 
can secrete cytokines such as IFN-γ and TNF-α in order to activate other components of 
the immune system. Like CD4+ T cells, CD8+ T cells can differentiate into effector and 
central memory T cells (12). 
C. B Cell Responses 
 Naïve B lymphocytes express antigen-specific immunoglobulin molecules on 
their cell surface. These receptors allow B cells to efficiently capture antigen from the 
extracellular environment. B cells then process and present this antigen in the context of 
MHC-II to CD4+ T cells in the lymph node. Cytokines, notably IL-4 from Th2 cells, in turn 
activate the naïve B cells to become antibody-secreting plasma cells. The antibodies 
secreted by plasma cells are better specialized for targeting a specific antigen due to the 
processes of immunoglobulin class switching and affinity maturation that occur during 
plasma cell differentiation (13). Antibodies play a number of roles in immunity including 
neutralization, opsonization, and complement activation. After infection, antigen-specific 
memory B cells maintain expression of their high affinity, class-switched antibody (1). 
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IV. Overview of Autoimmunity 
 Normally the innate and adaptive branches of the immune system work 
exquisitely in concert to efficiently clear an infection and mount a memory response that 
will prevent the host from becoming ill again should reinfection occur. To accomplish this 
task, the immune system relies on its ability to distinguish self from non-self. 
Unfortunately in some instances, undesirable adaptive immune responses can be 
mounted against the body’s own self-antigens, a condition known as autoimmunity. 
 A number of tolerance mechanisms normally prevent the development of 
autoimmunity. For example, central tolerance mechanisms promote the deletion of 
autoreactive T and B cells during their development in the thymus and bone marrow, 
respectively. Additionally, the activity of Treg cells can suppress the development of 
autoimmunity in the periphery by secreting anti-inflammatory cytokines such as IL-10 
and transforming growth factor-β. Treg cell activity is an example of a peripheral 
tolerance mechanism. Autoimmunity can ensue when these central and peripheral 
tolerance mechanisms fail (1). 
V. Type I Diabetes 
 Type I diabetes mellitus (TIDM), also referred to as insulin-dependent diabetes 
mellitus, is an organ-specific, T cell-mediated autoimmune disease that results in the 
targeted destruction of pancreatic beta cells. These cells, located within the pancreatic 
islets of Langerhans, are responsible for secreting insulin, a hormone that, during a fed 
state, stimulates the cellular uptake of glucose and other biofuel sources from the blood. 
During TIDM, the other pancreatic islet cell types, such as glucagon-secreting alpha 
cells, remain intact. Glucagon is a hormone that promotes fat breakdown in adipose 
tissue, protein breakdown in muscle and other tissues, and gluconeogenesis in the liver. 
The loss of insulin during TIDM, with continued secretion of glucagon, effectively results 
in a state of accelerated starvation. Before the implementation of insulin therapy in the 
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early 1920s, children with TIDM suffered an agonizing illness characterized by weight 
loss, cachexia, and overwhelming acidosis. Most patients passed away within one or two 
years of diagnosis (14). 
A. Etiology 
 In the United States and Europe, nearly 1 in 600 children will develop TIDM in 
their lifetime (14). Although the precise sequence of events leading to TIDM 
development remains unclear, both genetic and environmental risk factors appear to 
play a role in disease susceptibility. The inheritance of TIDM appears to be polygenic 
(15). By far the strongest genetic determinant is the MHC genotype of the individual. 
Certain MHC-II DR3 and DR4 alleles are present in at least 90 percent of cases. Other 
genes known to contribute to TIDM susceptibility include PTPN22, IL2RA, and CCR5, all 
of which play a role in the immune system. Also the INS gene, which encodes insulin, is 
itself a candidate causal gene (16). 
 Although strong genetic associations with TIDM have been identified, the 
concordance rate of TIDM in monozygotic twins is only 50 percent, suggesting 
environmental risk factors also play an important role (15). Environmental risk factors 
thought to contribute to TIDM development include viral infections, specifically infections 
with coxsackieviruses and other enteroviruses, and dietary risk factors, such as early 
exposure to cow’s milk (17). 
B. Pathogenesis 
 Although genetic and environmental risk factors are thought to contribute to 
disease susceptibility, having one or more of these risk factors, or even some degree of 
autoimmunity, does not necessarily mean an individual will develop TIDM. Rather 
pancreatic beta cell mass must decrease to a certain threshold for clinical symptoms of 
the disease to manifest. By the time overt diabetes sets in, some patients have lost up to 
90 percent of their original beta cell mass (Figure 3) (18). However, the precise 
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contributions of infiltrating immune cells and the beta cells themselves to this pathogenic 
loss of beta cell mass remain unclear.  
Regarding the immune system, it has long been proposed that an ill-defined 
environmental trigger (Figure 3), such as a viral infection, results in the release of beta 
cell autoantigens, such as insulin and glutamic acid decarboxylase (GAD), into the 
extracellular environment. These autoantigens are then scavenged by APCs and 
presented in the context of MHC-II to autoreactive CD4+ T cells, which have previously 
escaped selection in the thymus, in nearby lymph nodes. These CD4+ T cells in turn 
activate B cells to produce autoantibodies and cytotoxic CD8+ T cells to directly kill beta 
cells by secreting perforin and granzyme and engaging the death receptor FAS (19).
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accumulate. Beta cells are particularly sensitive to ER stress due to the high basal level 
of protein synthesis that occurs in these cells. Twenty percent of total protein 
synthesized in beta cells is proinsulin, the precursor of insulin. Thus, additional demands 
in protein synthesis resulting from immune-mediated stress may result in ER stress and 
beta cell death. Beta cells are particularly sensitive to ROS-mediated oxidative stress 
due to their unique lack of catalase, an enzyme required to breakdown H2O2. Beta cells 
paradoxically produce high basal levels of H2O2 due to their unique metabolic 
programming. Unlike other cell types, in which pyruvate generated during glycolysis can 
be shuttled to a number of different metabolic pathways, most of the pyruvate produced 
in beta cells is channeled to the tricarboxylic acid cycle in the mitochondria. This process 
generates high levels of oxygen radicals, which are converted to H2O2 by the enzyme 
superoxide dismutase 2. Thus, any additional ROS produced in response to stress-
induced signaling is likely to be detrimental to beta cells (19).  
Hyperglycemia resulting from the progressive loss of beta cell mass can further 
exacerbate these problems, thus leading to even more beta cell death. High levels of 
glucose in the blood will increase the demand for proinsulin synthesis by the remaining 
beta cells, thus contributing to a possible increase in ER stress (19; 20). Furthermore, 
elevated levels of glucose will result in more pyruvate being shuttled to the tricarboxylic 
acid cycle and increased generation of ROS. Due to these unique beta cell-specific 
vulnerabilities to immune-mediated stressors, a current view purports that TIDM results 
from immune-mediated, albeit self-assisted, beta cell death (19). 
C. Clinical Significance 
 Currently TIDM can be well-managed with a combination of recombinant human 
insulin, designer insulin analogues, high-tech insulin pumps, and state-of-the-art insulin 
sensors. The discovery and clinical implementation of these therapeutic advancements 
represent remarkable achievements in modern medicine (21). Patients with TIDM now 
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survive and live their lives with a disease that, less than a century ago, was fatal; 
however, TIDM is still an incurable, progressive disease with significant, if not life-
threatening, complications. Some of these complications include diabetic retinopathy, 
nephropathy, neuropathy, foot ulcers, and cardiovascular diseases (20; 21).  
Because TIDM is a chronic illness that requires lifelong management, this 
disease is a great financial burden to both individual patients and our country as a 
whole. A patient living with TIDM can incur up to $10,000 dollars per year in standard 
healthcare costs, while each year TIDM costs our country over $14.4 billion dollars in 
medical costs and lost income (22). Thus, eliminating TIDM remains a critically important 
objective. Understanding processes such as ER stress that contribute to beta cell death 
and TIDM progression will be necessary to develop better therapies and prevention 
strategies for this chronic disease. 
VI. The Unfolded Protein Response 
 To combat ER stress, mammalian cells have evolved a three-pronged, 
cytoprotective signal transduction pathway known as the unfolded protein response 
(UPR). To induce the UPR, three ER-associated transmembrane proteins are utilized: 
inositol requiring enzyme 1 (IRE1), dsRNA-dependent protein kinase R (PKR)-like ER 
kinase (PERK), and activating transcription factor (ATF) 6. Normally, these proteins are 
rendered inactive by their association with the ER chaperone binding immunoglobulin 
protein (BiP). During ER stress, BiP dissociates from IRE1, PERK, and ATF6 in order to 
assist with protein folding, thus allowing these proteins to initiate signal transduction. The 
goal of UPR activation is to restore ER homeostasis by increasing the expression of 
chaperones to assist with protein folding, while simultaneously halting translation of 
proteins not involved in mitigating ER stress. The UPR also activates the ER-associated 
degradation pathway (ERAD), which targets misfolded proteins to the proteasome for 
degradation (23). 
17 
 The UPR sensor IRE1 is a transmembrane protein that has both endonuclease 
and kinase activities. IRE1 autophosphorylation activates its endonuclease activity, 
which is responsible for the unconventional, cytosolic splicing of XBP1 mRNA. XBP1 
mRNA encodes the transcriptional repressor X-box binding protein 1 (XBP1). Splicing of 
XBP1 to XBP1s produces a transcript encoding the activating transcription factor XBP1s, 
which induces the expression of genes encoding ER chaperones as well as ERAD 
components. IRE1 endonuclease activity also promotes the degradation of mRNAs in a 
process known as regulated IRE1-dependent decay (RIDD) (23). IRE1 kinase activity is 
less well understood; however, it is known to result in the activation of JNK. JNK 
activation may promote cell survival by inducing autophagy or induce apoptosis in cells 
with unsurmountable levels of ER stress (Figure 4) (24). 
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The UPR sensor PERK, activated by transphosphorylation following BiP 
dissociation, phosphorylates the translation initiation factor eIF2α. Phosphorylation of 
eIF2α inhibits synthesis of new secretory proteins, while simultaneously promoting 
translation of ATF4, a transcription factor that induces expression of genes involved in 
amino acid metabolism and oxidative stress resistance, in addition to genes encoding 
ER chaperones (23). In the case of unresolvable ER stress, ATF4 promotes the 
transcription of DDIT3, which encodes CCAAT/enhancer-binding protein homologous 
protein (CHOP), a transcription factor that upregulates genes involved in apoptotic cell 
death. ATF4 also promotes transcription of ATF3, which encodes a transcription factor 
known to suppress the expression of genes encoding pro-inflammatory cytokines 
(Figure 4) (24; 25). 
 Activation of the UPR sensor ATF6 results in its translocation to the Golgi 
apparatus where it is cleaved by site proteases S1P and S2P. Truncated ATF6 then 
translocates to the nucleus where it induces expression of genes involved in protein 
folding and transport, ERAD, and lipid biosynthesis. Here ATF6 also induces 
transcription of DDIT3, HSPA5, which encodes BiP, and XBP1, thus amplifying the UPR 
(Figure 4) (23). 
VII. Pro-Inflammatory Cytokines and Beta Cell ER Stress and Death 
 As mentioned above in the discussion of TIDM pathogenesis, the pro-
inflammatory cytokines IL-1β, TNF-α, and IFN-γ are known to contribute to ER stress 
and beta cell death. These cytokines are released by activated macrophages, NK cells, 
and T cells during the course of insulitis, the TIDM-associated infiltration of immune cells 
into the pancreatic islets (Figure 5) (26). Pro-inflammatory cytokines contribute to the 
induction of ER stress in beta cells via different mechanisms, depending on the species 
of origin. Studies in rat beta cells have shown that pro-inflammatory cytokines contribute 
to ER stress and apoptosis through NO-dependent downregulation of sarco-
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endoplasmic reticulum Ca2+ ATPase (SERCA) 2b, an ER calcium pump. In this study, 
decreased expression of SERCA2b resulted in ER Ca2+ depletion and ER stress 
induction (27).  However, more recent studies have shown that cytokine-induced 
apoptosis does not require the production of NO in mouse beta cells or human islet cells. 
Rather, cytokine-induced ER stress was found to mediate apoptosis of human beta cells, 
at least in part, by activation of JNK (28). 
ROS production can contribute to ER stress by targeting chaperones as well as 
ER Ca2+ channels, the latter of which could result in the leakage of Ca2+ from the ER to 
the cytosol. The leakage of Ca2+ from the ER contributes to ER stress because the 
concentration of ER Ca2+ is critical for maintaining proper chaperone function and protein 
folding in the ER. Calcium released from the ER eventually becomes concentrated in the 
mitochondria where it disrupts electron transport, thus promoting even more ROS 
generation (29).  Thus, although NO was found to be dispensable for ER stress 
induction in human beta cells, other ROS may contribute to ER stress induction in these 
cells. 
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secreting beta cells remain to inhibit overt hyperglycemia and other clinical symptoms of 
disease (21).   
A major obstacle in the road to developing effective prevention strategies for 
TIDM is the lack of known, specific biological markers that could detect individuals 
undergoing this clinically latent period of beta cell stress (21). If such markers could be 
identified, the implementation of TIDM prevention strategies, such as the use of anti-
CD3 or anti-CD20 monoclonal antibodies, could be optimized, perhaps through better 
timing or the co-administration of drugs to preserve beta cell function (19). Anti-CD3 and 
anti-CD20 therapies, which deplete T and B lymphocytes, respectively, have shown 
promise in preventing TIDM in a number preclinical and clinical studies (30). 
IX. Current Biomarkers for TIDM 
 Currently a number of biomarkers for TIDM have been identified. For example, 
serum autoantibody markers have been established for the following beta cell 
autoantigens: insulin, GAD, tyrosine phosphatase-like insulinoma antigen 2, C-terminal 
epitope of IA2, and zinc transporter 8 (Table 1). These autoantibody markers are used 
to confirm TIDM diagnosis in the clinic (21). In addition to serum autoantibodies, other 
biomarkers for TIDM include serum cytokines, such as CXCL1; beta cell-specific 
epigenetic changes, such as unmethylated insulin DNA; and beta cell stress-induced 
miRNAs and proteins (21). Some have speculated markers of ER stress, such as 
CHOP, could be used as biomarkers for beta cell destruction in the clinic, but detecting 
changes in expression levels of beta cell proteins in vivo remains challenging (20; 21). 
 Recently collaborative studies between our laboratory and others have shown 
that proinsulin to C-peptide ratios are elevated in patients with newly diagnosed TIDM 
compared to body mass index (BMI), age, and gender matched control subjects. This 
result suggests that proinsulin is not processed correctly to C-peptide and mature insulin 
in newly diagnosed patients with TIDM. This lack of optimal post-translational processing 
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would be expected to occur in stressed beta cells. Furthermore, this same study found 
that serum levels of heat shock protein (HSP)90 were elevated in patients newly 
diagnosed with TIDM relative to controls (31). However, whether the presence of this 
protein in the serum is indicative of beta cell stress characteristic of latent TIDM is 
unclear. 
Antigen Association with TIDM
Insulin (IAAs)  Detected in 60% of newly diagnosed children
Glutamic acid decarboxylase (GAD) Detected in 70-80% of newly diagnosed 
individuals 
Tyr phosphatase-like insulinoma 
antigen 2 (IA2) 
Detected in 60% of newly diagnosed 
individuals 
C-terminal epitope of IA2 (ICA512) Detected in 70-80% of newly diagnosed 
individuals 
Zinc transporter 8 (ZnT8) Detected in 60% of newly diagnosed 
individuals 
 
Table 1. Established serum autoantibody markers used in the diagnosis of TIDM. 
The presence of any of the autoantibodies listed above in patient serum is used to 
distinguish TIDM from type II diabetes in the clinic. However, TIDM can still be present in 
autoantibody negative individuals. Other TIDM biomarkers that can be identified include 
serum cytokines, beta cell-specific epigenetic changes, miRNAs, and proteins. However, 
a critical need exists for the identification of new biomarkers that could distinguish 
individuals in the latent period of TIDM (Figure 3). If patients could be identified before 
beta cell mass is completely obliterated, preventative therapies could be more 
successfully implemented to preserve beta cell mass and prevent the progression to 
TIDM. 
X. HSP90 
 HSP90 is a highly conserved member of the heat shock protein family of 
molecular chaperones. These proteins, upregulated in response to heat, are an essential 
component of the heat shock response. HSP90, in cooperation with co-chaperone 
proteins, assists a wide variety of protein clients in the acquisition of their active 
conformations by using energy derived from ATP binding and hydrolysis. HSP90 client 
proteins are involved in numerous cellular processes including signal transduction, 
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protein trafficking, receptor maturation, as well as innate and adaptive immunity. Human 
beings express four isoforms of HSP90: GRP94, the ER isoform; TRAP1, the 
mitochondrial isoform; and two cytoplasmic isoforms, HSP90α and HSP90β. 
Cytoplasmic HSP90 is one of the most abundant proteins in the cell, comprising 1-2 
percent of total protein levels (32). 
A. HSP90 Associations with Human Autoimmune Disease 
 Our laboratory became interested in studying HSP90 in the context of TIDM due 
to numerous associations of this protein with autoimmune disease. For example, skin 
and peripheral blood mononuclear cell (PBMC) levels of HSP90 were found to be 
elevated in patients with bullous pemphigoid, an autoimmune skin blistering disease, 
compared to control subjects (33). Another study revealed elevated levels of HSP90 in 
PBMCs from patients with systemic lupus erythematosus (SLE). These authors also 
found that increased levels of intracellular HSP90 in PBMCs correlated with increased 
levels of IL-6 and IgG autoantibodies to HSP90 in the serum of patients with SLE (34). 
 Furthermore another study found that although both control subjects and patients 
with TIDM had circulating autoantibodies to HSP90, patients with TIDM had higher levels 
of circulating IgG1 and IgG3 class-switched autoantibodies to this protein. These 
isotypes of antibody are most commonly produced during Th1-mediated immune 
responses, which predominate the autoimmune response in TIDM (35). This data led us 
to question whether or not HSP90 protein could be released from cells during the 
development of TIDM. 
B. HSP90 Inhibition and Murine Models of Autoimmune Disease 
 Interestingly, pharmacological inhibition of HSP90 chaperone function has shown 
beneficial effects in a number of animal models of autoimmune disease. In the MRL/lpr 
mouse model of SLE, animals treated with the HSP90 inhibitor 17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) exhibited reduced 
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proteinuria, serum anti-dsDNA autoantibodies, and follicular B cells (36). In a mouse 
model of epidermolysis bullosa acquisita, a skin blistering disease associated with 
autoimmunity to type VII collagen, 17-DMAG treatment reduced total splenic B cells 
while increasing splenic regulatory B cells. Mice treated with 17-DMAG also displayed 
lower levels of circulating autoantibodies in this study (37). Application of another 
inhibitor of HSP90, SNX-4414, resulted in reduced inflammation, swelling, and cartilage 
damage in rat models of rheumatoid arthritis (38). Similarly, the HSP90 inhibitor EC144 
suppressed inflammatory responses in two rodent models of autoimmune arthritis (39).  
 In addition to these effects observed in models of autoimmune diseases 
mediated by pathogenic autoantibodies, HSP90 inhibition has also shown beneficial 
effects in models of T cell-mediated autoimmune diseases. Treatment with 17-
allylamino-17-demethoxygeldanamycin (17-AAG), another HSP90 inhibitor, prevented 
the onset of experimental autoimmune encephalomyelitis, the murine model of multiple 
sclerosis. This study also found that T cells from 17-AAG-treated mice produced less IL-
2 in response to in vitro re-stimulation with peptide antigen (40). Others have shown in 
vitro that 17-DMAG inhibits T cell proliferation, decreases CD4+ T cell expression of IFN-
γ and IL-17, and reduces secretion of IFN-γ, TNF-α, and IL-17 in anti-CD3 stimulated 
human PBMC cultures (41).  
Taken together, these studies suggest HSP90 may play a role in the 
pathogenesis of autoimmune diseases. However, precisely how HSP90 could be 
regulating immune responses is not yet clear. Nevertheless, other studies have 
suggested specific roles for this protein in modulating immune responses. 
C. HSP90 and Immune Responses 
 A role for HSPs, including HSP90, in immunity was revealed nearly thirty years 
ago with the discovery that HSPs purified from cancer cells could illicit immunity to 
tumors, while HSP preparations from normal tissues could not. This immunogenicity was 
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found to result from the association of HSPs with tumor-specific antigens. These HSP-
antigen complexes could be taken up by APCs through association with the HSP 
receptor CD91. This receptor-mediated uptake of HSP-antigen complexes both 
promoted antigen processing within the APCs and increased presentation of tumor-
associated antigens to T cells in the context of MHC molecules (42). Interestingly, our 
laboratory discovered a potential mechanism by which HSP90 could promote antigen 
presentation in the context of TIDM. In human B lymphoblasts, HSP90 was found to 
associate with and promote MHC-II presentation of the TIDM-associated autoantigen 
GAD (43). 
 Other studies have pointed to a role for HSPs in promoting innate immune 
responses. HSPs were found to promote both dendritic cell migration to lymph nodes as 
well as dendritic cell maturation, measured by cell surface expression of MHC-II, CD86, 
and CD40. HSPs have also been shown to promote the production of pro-inflammatory 
cytokines such as IL-1β and TNF-α as well as the induction of iNOS and subsequent 
production of NO in APCs. These activities are remarkably similar to the effects of LPS 
activation on dendritic cells and macrophages (42).  
 Researchers have suggested that HSPs are able to activate the immune system 
by functioning as damage-associated molecular patterns (DAMPs), molecules that 
activate an immune response via mechanisms similar to PAMPs. However, whether or 
not DAMPs contain specific molecular patterns that are recognized by the immune 
system is unclear at present. Rather these molecules can be thought of as danger 
signals of non-microbial origin. Instead of infection, DAMPs alert the immune system to 
danger brought on by non-physiological cell death, damage, or stress. These molecules 
are normally contained within the cytoplasm of live cells, but upon cell stress, damage, 
or death, are released into the extracellular environment where they can activate the 
immune system (44).  
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 Indeed beta cell death and the subsequent release of DAMPs are thought to 
contribute to autoimmunity in animal models of TIDM, including the non-obese diabetic 
(NOD) mouse model (44). NOD mice spontaneously develop a T cell-mediated disease 
that shares many similarities with human TIDM, including the early development of 
insulitis and production of beta cell-specific autoantibodies (45). Treatment of NOD mice 
with a pan-caspase inhibitor to prevent apoptosis blocked the activation of diabetogenic 
T cells (46). In another study, inducing beta cell death using multiple, small doses of 
streptozotocin was found to induce pancreatic insulitis and subsequent diabetes in mice 
(47). 
 Furthermore one study found that HSP90, GRP94, and HSP70 are released 
during necrotic cell death, and that purified preparations of these proteins can deliver 
maturation signals to dendritic cells, resulting in activation of the NF-κB pathway and 
secretion of pro-inflammatory cytokines. This study made use of an LPS antagonist Rslp 
to rule out the effects of contaminating endotoxin on dendritic cell stimulation (48).  
Nevertheless, although numerous studies have identified a role for DAMPs, such 
as high mobility group box 1 (HMGB1) protein, in activating the innate immune system, 
the ability of HSPs to trigger an innate immune response remains unclear (44). Contrary 
to the study described above, other studies have shown that highly purified, endotoxin-
free HSPs are unable to activate APCs (49; 50). Further experiments testing the effects 
of HSP depletion on the adjuvant activity of dead cells are needed to clarify these 
contradictory results. As numerous HSPs could possibly be working together to produce 
these effects, such experiments will not be trivial (44). 
D. Extracellular HSP90 
 Although whether extracellular HSP90 functions as a DAMP to activate APCs 
and initiate innate immune responses is still unclear, several studies suggest that this 
protein is released from cells into the extracellular environment during stress. In 
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response to heat shock, B lymphoblastoid cell lines were found to release elevated 
levels of HSP90 in extracellular vesicles known as exosomes (51). Exosomes are cell-
derived vesicles formed by the inward budding of multivesicular body membranes. 
Multivesicular bodies are cellular compartments of endocytic origin that release 
extracellular vesicles out of the cell into the extracellular environment. Once released 
exosomes are known to perform functions in intercellular communication and biological 
signaling (52). However, B cell-derived exosomes in the study described above were 
unable to trigger dendritic cell maturation (51). 
 Another study reported that oxidative stress results in HSP90 secretion from 
vascular smooth muscle cells. These authors proposed that HSP90 was responsible for 
subsequent activation of ERK1/2 in these cells (53), and this pathway is known to be 
required for cell growth (54). Furthermore, HSP90 was found to be secreted by human 
fibroblasts in response to hypoxia and HIF-1α activation. In these studies, HSP90 was 
found to promote fibroblast migration and wound healing (55). Although HSP90 has 
been shown to be secreted by normal cells during various forms of stress, tumor cells 
are known to secrete HSP90 constitutively (54). 
 In cancer, extracellular HSP90 is widely thought to contribute to cancer cell 
motility and metastasis. Although the specific mechanisms leading to HSP90 secretion 
from tumor cells are not well understood, HSP90 release is known to be stimulated by 
environmental stressors and growth factors (56). At the molecular level, HSP90 
secretion is regulated by post-translational modifications such as phosphorylation and 
acetylation (56; 57). Extracellular HSP90 can stimulate cancer cell invasiveness by 
activating matrix metalloproteinase-2 (MMP-2) (58). It can also stimulate migration 
through binding the cell surface receptor CD91 independently of its ability to bind and 
hydrolyze ATP (56). 
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XI. Research Goals 
 In a recent study carried out by our laboratory and others, HSP90 was found to 
be elevated in the serum of newly diagnosed patients with TIDM relative to control 
subjects, thus identifying this protein as a potential biomarker of beta cell stress (31). 
Class-switched anti-HSP90 autoantibodies are also elevated in patients with TIDM, 
suggesting this protein may be released extracellularly during TIDM development (35). 
Furthermore many other studies have shown HSP90 is secreted in response to cellular 
stress (54). In light of this information, we hypothesized HSP90 may be released from 
pancreatic beta cells in response to cellular stress events associated with the latent 
period of TIDM.  
The first goal of this project was to understand what stimuli could induce release 
of HSP90 from pancreatic beta cells. To investigate this aim, two human pancreatic beta 
cell lines, βLox5 and 1.1B4, were used. Experiments were also carried out using the 
murine insulin-secreting cell line MIN6 and primary human cadaveric islets isolated from 
non-diabetic donors. To specifically test the hypothesis that pancreatic beta cells release 
HSP90 in response to cellular stress, cells were treated in vitro with thapsigargin, pro-
inflammatory cytokines, high glucose growth medium, and TLR agonists for 24 hours, 
and HSP90 release was measured by ELISA. 
The next goal for this project was to elucidate the intracellular signaling events 
that contributed to HSP90 release from pancreatic beta cells in response to specific 
stressors. Various pharmacological inhibitors and other drugs were used with our in vitro 
cell culture systems in an attempt to block HSP90 release. The goal of these 
experiments was to determine a specific signaling pathway that was important for driving 
HSP90 release. As part of these first two aims, various stress pathways were 
characterized by measuring expression levels of specific genes and proteins associated 
with these pathways. 
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The final goal of this work was to investigate the role of HSP90 activity in the 
development of TIDM in vivo. Female NOD mice were treated with the HSP90 inhibitor 
17-DMAG over the course of several weeks, and TIDM development was monitored via 
weekly measurements of body weight and blood glucose. Insulitis in these mice was 
characterized by histology, while stress responses in islet cells by were analyzed by 
measuring expression levels of stress-associated genes. 
The overall objective of this work was to confirm that extracellular HSP90 is a 
marker of pancreatic beta cell stress associated with the latent period of TIDM. If true, 
serum levels of HSP90 could potentially be measured in the clinic as a biomarker to 
identify patients in this pre-clinical period of disease. Thus, the implementation of 
treatments aimed at TIDM prevention could be more accurately applied, better timed, 
and optimized with other treatments aimed at restoring and preserving beta cell mass. 
The outcome of these therapies would be to halt the progression of at-risk patients to 
insulin dependence and lifelong TIDM. 
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MATERIALS AND METHODS 
Cell culture 
The human pancreatic beta cell line βLox5 (59) was kindly provided by Dr. 
Clayton E. Mathews (University of Florida). These cells were maintained in Dulbecco’s 
modified Eagle medium (DMEM) containing 1 g/L D-glucose and 110 mg/L sodium 
pyruvate (Gibco). Media was supplemented with 10% characterized fetal bovine serum 
(FBS) (HyClone), 15 mM HEPES buffer (Corning), 50 U/mL penicillin and 50 μg/mL 
streptomycin (Corning), 2 mM L-glutamine (Corning), 1X minimal essential medium non-
essential amino acids (Gibco), and 0.02% bovine serum albumin (BSA)  (Sigma-Aldrich). 
To passage, media was aspirated and monolayers were washed twice with Hanks’ 
balanced salt solution (HBSS) (Corning). Cells were then incubated with 0.25% trypsin 
with 2.21 mM ethylenediaminetetraacetic acid (EDTA) (Corning) for 8 minutes at 37°C. 
Detached cells were collected and washed with complete medium, and cell viability was 
determined by trypan blue staining. 1.25-5 x 105 cells were seeded into 100 mm tissue 
culture plates (Corning) containing 10 mL complete medium. Cells were grown at 37°C 
with 7% CO2. Media was replaced every 2-3 days. Cells were passaged at 100% 
confluency and discarded after eight passages.  
The human pancreatic beta cell line 1.1B4 (60) was also provided by Dr. Clayton 
E. Mathews (University of Florida). 1.1B4 cells were maintained in Roswell Park 
Memorial Institute (RPMI) 1640 media with L-glutamine (Corning) supplemented with 
10% characterized FBS, 50 U/mL penicillin and 50 μg/mL streptomycin, and 2 mM L-
glutamine. To passage, media was aspirated and monolayers were washed twice with 
HBSS. Cells were then incubated with 0.25% trypsin with 2.21 mM EDTA for 10 minutes 
at 37°C. Detached cells were collected and washed with complete medium, and viability 
was determined by trypan blue exclusion. 2.5-5 x 105 cells were seeded into 100 mm 
tissue culture plates containing 10 mL complete medium. Cells were grown at 37°C with 
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7% CO2. Media was replaced every 2-3 days. Cells were passaged at 90% confluency 
and discarded after eight passages. 
Human primary cadaveric islets were obtained from the Integrated Islet 
Distribution Program (City of Hope). Minimal health information was provided with islet 
preparations; however, donors were adults ranging from 28-52 years of age with no 
medical history of type II diabetes (Table 2). Upon receipt islets were rested by 
incubation for one hour at 37°C to allow recovery after transit. Whole islets were sorted 
by microscopic inspection and hand-picking from debris and then maintained in 
Connaught Medical Research Laboratories (CMRL) 1066 media (Gibco) supplemented 
with 10% FBS (HyClone), 50 U/mL penicillin and 50 μg/mL streptomycin, and 2 mM L-
glutamine. Islets were cultured in 35 mm petri dishes (Celltreat) at 37°C with 7% CO2. 
Following in vitro stress treatments, approximately 20 whole islets were washed twice 
with Dulbecco’s phosphate-buffered saline (DPBS) (Corning) and digested into a single 
cell suspension with 0.25% trypsin containing 2.21 mM EDTA for 15 minutes at 37°C. 
Cell viability was then determined by trypan blue staining. 
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Donor Sex Age BMI 
1 M 40 38.9 
2 M 36 33.8 
3 F 39 45.2 
4 F 47 22.5 
5 M 28 22.9 
6 M 48 31.2 
7 M 43 36.5 
8 F 39 25.9 
9 F 52 31.4 
 
Table 2. Human islet donor sex, age, and BMI data. Human islets isolated from non-
diabetic cadaveric donors were obtained from the Integrated Islet Distribution Program 
(City of Hope). Islets from male and female donors aged 28-52 were used for in vitro 
stress treatments. 
The murine insulinoma cell line MIN6 was kindly provided by Dr. Debbie 
Thurmond (City of Hope). MIN6 cells were maintained in DMEM containing 4.5 g/L 
glucose, L-glutamine, and sodium pyruvate (Corning) supplemented with 10% 
characterized FBS, 50 U/mL penicillin and 50 μg/mL streptomycin, 2 mM L-glutamine, 
and 55 μM 2-mercaptoethanol (Gibco). To passage, media was aspirated and 
monolayers were washed twice with DPBS. Cells were then incubated with 0.25% 
trypsin with 2.21 mM EDTA for 10 minutes at 37°C. Detached cells were collected and 
washed with complete medium. Cells were then split 1:5 into new 100 mm tissue culture 
plates. Cells were grown at 37°C with 7% CO2. Media was replaced every 2-3 days. 
Cells were passaged at 80-90% confluency and discarded after eight passages. 
Cryopreservation 
βLox5 and 1.1B4 cells were suspended at 3 x 105 – 1 x 106 cells/mL in freezing 
medium composed of 10% dimethyl sulfoxide (Corning), 40% characterized FBS, and 
50% βLox5 or 1.1B4 tissue culture media. Aliquots of 1 mL were then transferred to 
CryoTube vials (Thermo Scientific). Vials were placed at -80°C in Nalgene cryo 1°C 
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freezing containers filled with 500 mL isopropanol to achieve a cooling rate of -1°C per 
minute. After 24 hours, vials were transferred to liquid nitrogen tanks. 
In Vitro Stress Treatments of Beta Cell Lines and Primary Human Cadaveric Islets 
For all in vitro stress treatment experiments, βLox5 and 1.1B4 cells were treated 
at approximately 90% confluency, MIN6 cells at 70-80% confluency, and primary human 
cadaveric islets at a density of 200 islets/1.5 mL, unless otherwise noted in a particular 
experiment. As a control, cells were treated with media alone unless otherwise noted.  
To test the effects of cytokine stress on human beta cell lines and primary 
cadaveric islets, cells were treated for various time points with a 100X cocktail of pro-
inflammatory cytokines prepared in DPBS + 0.01% BSA. Specifically, human beta cell 
lines and primary cadaveric islets were treated with final concentrations of 5 ng/mL 
human recombinant IL-1β (eBioscience), 10 ng/mL human recombinant TNF-α 
(PeproTech), and 100 ng/mL human recombinant IFN-γ (PeproTech). In βLox5 cells, the 
effects of individual cytokines were also tested by treating cells with identical 
concentrations of cytokine, either individually or in pairs. MIN6 cells were treated with 
final concentrations of 5 ng/mL murine recombinant IL-1β (eBioscience), 10 ng/mL 
murine recombinant TNF-α (PeproTech), and 100 ng/mL murine recombinant IFN-γ 
(PeproTech). 
To induce ER stress in beta cell lines, βLox5, 1.1B4, and MIN6 cells were treated 
in vitro with 1 μM thapsigargin (Cayman) for 6 hours or 0.1 μM thapsigargin for 24 hours. 
To test the effects of glucotoxicity on beta cell lines, βLox5, 1.1B4, and MIN6 
cells were treated for 6 or 24 hours with their respective culture medium supplemented 
to a final D-glucose (Sigma) concentration of 6 g/L (33.3 mM). 
To stimulate TLR3 signaling, βLox5 cells were treated with 0.1 μg/mL of the 
synthetic dsRNA analogue polyinosinic-polycytidylic acid (PIC) (Santa Cruz 
Biotechnology, Inc.) for 24 hours. Transfection of PIC into cells was achieved using 
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Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Briefly, PIC 
was diluted to 0.002 μg/μL in serum and BSA-free tissue culture media. Lipofectamine 
2000 was diluted to 40 μL/mL in serum and BSA-free media, mixed with an equal 
volume of diluted PIC, and incubated for 5 minutes at room temperature. A volume of 
100 μL PIC/Lipofectamine 2000 was added to βLox5 cells in 12-well tissue culture plates 
containing 900 μL complete tissue culture medium, for a final concentration of 0.1 μg/mL 
PIC and 2 μL/mL Lipofectamine 2000. As a control, βLox5 cells were treated with 100 μL 
serum/BSA-free medium containing Lipofectamine 2000 alone. 
To initiate TLR4 signaling, βLox5 cells were treated with 1 μg/mL LPS (Sigma-
Aldrich) for 24 hours. 
Inhibitor Studies 
To block various stress-associated responses in βLox5 cells, several inhibitors 
were used. Cells were treated with inhibitors for 6 hours prior to 24 hour stress treatment 
with pro-inflammatory cytokines or PIC. Optimal concentrations of inhibitors were 
determined in pilot experiments assessing cell viability and drug effectiveness. βLox5 
cells were treated with 100 μM 1400W (Cayman) to inhibit iNOS activity, 10 nM 
chetomin (Cayman) to inhibit HIF-1α activity, 100 μM dimethyloxaloylglycine (DMOG) 
(Sigma-Aldrich) to stabilize HIF-1α, 0.2 mM and 1 mM N-acetylcysteine (NAC) (Sigma-
Aldrich) pH 7.4 to scavenge ROS, 0.2 mM and 1 mM tauroursodeoxycholic acid 
(TUDCA) (Millipore) to mitigate ER stress, 10 μM and 50 μM 4μ8c (Millipore) to inhibit 
IRE1 endonuclease activity, 10 μM SP600125 (Santa Cruz Biotechnology, Inc.) to inhibit 
JNK signaling, and 5 μM and 10 μM SB202190 (Sigma-Aldrich) to inhibit p38 signaling. 
Lactate Dehydrogenase (LDH) Cytotoxicity Assay 
βLox5 cell viability in response to in vitro stress treatments was determined using 
a commercially-available LDH cytotoxicity assay kit (Pierce). Volumes of 50 μL 
conditioned media were assayed in triplicate in 96-well plates according to the 
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manufacturer’s instructions. After background absorbance values at 680 nm were 
subtracted from absorbance values at 490 nm, viability was calculated according to the 
following equation: 
Viability = 100 – ((Sample A490 – Control A490)/(Maximum A490 – Control A490))*100 
Enzyme-Linked Immunosorbent Assay (ELISA) Kits 
After stress treatments, conditioned media was harvested from cells and spun at 
2000 rpm at 4°C in a tissue culture centrifuge to remove debris. Supernatants were 
transferred to clean microfuge tubes and stored at -20°C for analysis. Commercially-
available ELISA kits for human HSP90α (Enzo), human HSC70 (Cloud-Clone Corp.), 
human HSP70 (Enzo), human IFN-α (PBL Assay Science), and murine HSP90α 
(Biomatik) were used according to the manufacturers’ instructions. 
ELISA for Human IL-6 
After stress treatments, conditioned media was harvested and stored as 
described above. To detect extracellular IL-6, 96-well enzyme-linked immunosorbent 
assay/radioimmunoassay plates (Corning) were coated with 50 μL per well of 2 μg/mL 
anti-human IL-6 capture antibody (Invitrogen) in 0.1 M carbonate buffer (pH 9.2) and 
incubated overnight at 4°C. Plates were washed 4 times with DPBS (Gibco) containing 
0.05% Tween 20 (PBST) (Fisher Scientific) and blocked 1 hour at room temperature with 
DPBS + 1% BSA blocking buffer. A standard curve of 0-4 ng/mL recombinant human IL-
6 (PeproTech) and sample dilutions were prepared in tissue culture medium. Volumes of 
100 μL standards and samples were added to wells and incubated overnight at 4°C. 
Plates were washed 4 times with PBST and incubated 1 hour at room temperature with 
50 μL per well of 1 μg/mL anti-human IL-6 biotin conjugate (Invitrogen) in blocking 
buffer. Plates were washed 4 times with PBST and incubated 30 minutes at room 
temperature with 50 μL per well of 0.2 μg/mL streptavidin-horseradish peroxidase (HRP) 
(Thermo Scientific) in blocking buffer. Plates were washed 4 times with PBST and 
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incubated for approximately 30 minutes with 100 μL per well of 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) substrate (SurModics). Absorbance at 405 nm 
was measured, and IL-6 concentration was determined by interpolating absorbance 
values of samples into the known recombinant IL-6 standard curve. 
RNA Isolation and Complimentary DNA (cDNA) Synthesis 
βLox5 cells, 1.1B4 cells, MIN6 cells, and primary human cadaveric islets were 
harvested and washed 3 times with DPBS. After a final spin, DPBS was aspirated and 
cell pellets were frozen and stored at -80°C prior to RNA isolation. Murine islets were 
harvested by the Indiana University School of Medicine Islet and Physiology Core 
(Indianapolis, IN), washed 3 times with DPBS, and processed immediately for RNA 
isolation. Total cellular RNA was isolated using an RNeasy Mini Kit (Qiagen) according 
to the manufacturer’s instructions. Cells were lysed in buffer RLT (Qiagen) containing 
1% 2-mercaptoethanol (Sigma Aldrich) and homogenized using QiaShredder spin 
columns (Qiagen). On-column DNase digestion was also performed using the RNase-
free DNase Set (Qiagen). Next cDNA was synthesized from 0.05-1 μg of RNA using a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer’s instructions.  
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
To quantitate relative gene expression levels, 5.5 μL master mix containing 0.5 
μL of a specific TaqMan Gene Expression Assay (Applied Biosystems) and 5 μL of 
TaqMan Fast Universal PCR Master Mix (Applied Biosystems) was mixed with 100 ng of 
cDNA in 4.5 μL diethylpyrocarbonate-treated water (Invitrogen) in MicroAmp Fast Optical 
96-well Reaction Plates (Applied Biosystems). Each condition was run in duplicate or 
triplicate. Amplification of cDNA was achieved by qRT-PCR using the 7500 Fast Real-
Time PCR System (Applied Biosystems). Samples were initially denatured for 20 
seconds at 95°C and then put through 40-45 cycles of 15 seconds at 95°C and 1 minute 
38 
at 60°C. Commercially available assays for human ACTB, ATF3, ATF4, B2M, CA9, 
DDIT3, GAPDH, HIF1A, HSPA5, HSP90AA1, HSP90AB1, HSP90B1, IFI27, IFNA1, 
IFNB1, IL6, ISG15, NOS2, TLR2, TLR3, TLR4, TLR9, TRAP1, and VEGFA were used 
(Table 3). Additionally, a custom assay for human XBP1s was designed to detect the 
spliced version of this transcript (Table 4). Commercially available assays for murine 
Actb, Ddit3, Hif1a, Hmgb1, Hspa1b, Hspa5, Hsp90aa1, Hsp90ab1, Hsp90b1, Il6, Ins1, 
Map1lc3a, Nos2, Sqstm1, and Trap1 were also used (Table 5). Gene expression was 
presented as target mRNA levels detected relative to transcripts for endogenous control 
genes (delta CT method). These control or housekeeping transcripts were identified by 
screening beta cell lines and islets for abundant, broadly expressed transcripts which 
minimally varied with cell stress induction. Typically these control transcripts displayed 
less than one cycle of variation between untreated and stressed cell samples. For βLox5 
and 1.1B4 cells, GAPDH was used as an endogenous control transcript, while ACTB 
was used as a control for primary cadaveric islets. Actb was also used for MIN6 cells as 
well as murine islets. Genes that exhibited CT values greater than 35 were considered 
undetected (UD). 
  
39 
Gene Description Assay Product 
Number 
ACTB β-actin 4333762-1108032 
ATF3 Activating transcription factor 3 Hs00231069_m1 
ATF4 Activating transcription factor 4 Hs00909569_g1 
B2M β2-microglobulin 4333766-1006021 
CA9 Carbonic anhydrase IX Hs00154208_m1 
DDIT3 C/EBP homologous protein (CHOP) Hs00358796_g1 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs02758991_g1 
HIF1A Hypoxia-inducible factor 1, alpha subunit Hs00153153_m1 
HSPA5 Binding immunoglobulin protein (BiP) Hs00607129_gH 
HSP90AA1 Heat shock protein 90, α cytosolic isoform Hs00743767_sH 
HSP90AB1 Heat shock protein 90, β cytosolic isoform Hs01546478_g1 
HSP90B1 Heat shock protein 90, ER isoform (GRP94) Hs00427665_y1 
IFI27 Interferon, alpha-inducible protein 27 Hs01086373_g1 
IFNA1 Interferon-α 1 Hs00855471_g1 
IFNB1 Interferon-β 1 Hs01077958_s1 
IL6 Interleukin-6 Hs00985639_m1 
ISG15 Interferon-stimulated gene 15 Hs01921425_s1 
NOS2 Nitric oxide synthase, inducible (iNOS) Hs01075529_m1 
TLR2 Toll-like receptor 2 Hs01872448_s1 
TLR3 Toll-like receptor 3 Hs01551078_m1 
TLR4 Toll-like receptor 4 Hs00152939_m1 
TLR9 Toll-like receptor 9 Hs00152973_m1 
TRAP1 Heat shock protein 90, mitochondrial isoform Hs00212476_m1 
VEGFA Vascular endothelial growth factor A Hs00900055_m1 
 
Table 3. Human TaqMan gene expression assays. 
 
 
 
Component 
 
Sequence 
Forward Primer 5’ CCTGGTTGCTGAAGAGGAG 3’ 
Reverse Primer 5’ AGTCAATACCGCCAGAATCC 3’  
Probe 5’ CCTGCACCTGCTGCGGACTC 3’ 
 
Table 4. Custom XBP1s TaqMan gene expression assay sequences. 
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Gene Description Assay Product 
Number 
Actb β-actin 4352933-1112036 
Ddit3 C/EBP homologous protein (CHOP) Mm01135937_g1 
Hif1a Hypoxia-inducible factor 1, alpha subunit Mm00468869_m1 
Hmgb1 High mobility group box 1 Mm00849805_gH 
Hspa1b Heat shock protein 70 (HSP70) Mm03038954_s1 
Hspa5 Binding immunoglobulin protein (BiP) Mm00517690_g1 
Hsp90aa1 Heat shock protein 90, α cytosolic isoform Mm00658568_gH 
Hsp90ab1 Heat shock protein 90, β cytosolic isoform Mm00833431_g1 
Hsp90b1 Heat shock protein 90, ER isoform (GRP94) Mm00441926_m1 
Il6 Interleukin-6 Mm00446190_m1 
Ins1 Insulin Mm01950294_s1 
Mapk1lc3a Microtubule-associated protein 1 light chain 3 α 
(LC3) 
Mm00458725_g1 
Nos2 Nitric oxide synthase, inducible (iNOS) Mm00440502_m1 
Sqstm1 Sequestome 1 (p62) Mm00448091_m1 
Trap1 Heat shock protein 90, mitochondrial isoform Mm00446003_m1 
 
Table 5. Murine TaqMan gene expression assays. 
 
Exosome Isolation 
 To prepare cell culture media with serum for βLox5 exosome production, DMEM 
containing 1 g/L D-glucose and 110 mg/L sodium pyruvate was supplemented with 20% 
characterized FBS and centrifuged at 100,000 x g overnight at 4°C to remove serum-
derived bovine exosomes. The following morning, DMEM and additional supplements 
were added to yield complete βLox5 tissue culture medium containing 10% 
characterized FBS (see Cell Culture methods). 
 To isolate exosomes released in the media from βLox5 cells, complete media 
was aspirated and monolayers were washed twice with HBSS. Exosome production 
medium was added, and cells were treated and incubated as required per experiment. 
Following incubation, media was harvested into 15 mL conical tubes, and exosomes 
were precipitated from 4 mL of tissue culture media using ExoQuick-TC (System 
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Biosciences) according to the manufacturer’s instructions. To liberate exosome proteins 
for ELISA, Exosome Binding Buffer (System Biosciences) was used following the 
manufacturer’s instructions. HSP90 levels in exosome and soluble fractions were 
assayed by ELISA, and concentrations were multiplied by sample volume to give total 
amount of HSP90 in ng. 
Antibodies 
 The following antibodies were used to detect the abundance of specific proteins 
by immunoblotting. HSP90 was detected with the mouse monoclonal antibody clone 
AC88 (Enzo) diluted 1:1000 or with the rat monoclonal antibody clone 16F1 (Abcam) 
diluted 1:500. Phospho-SAPK/JNK (Thr183/Tyr185) was detected with the rabbit 
monoclonal antibody clone 81E11 (Cell Signaling Technology) diluted 1:500, while total 
SAPK/JNK was detected using a rabbit polyclonal antibody (Cell Signaling Technology) 
diluted 1:500. Phospho-p38 MAPK (Thr180/Tyr182) was detected with the rabbit 
monoclonal antibody clone D3F9 (Cell Signaling Technology) diluted 1:500, while total 
p38 MAPK was detected with a rabbit polyclonal antibody (Cell Signaling Technology) 
diluted 1:1000. Actin and GAPDH were immunoblotted as loading controls. Actin was 
detected with the mouse monoclonal antibody clone ACTN05 (C4) (NeoMarkers) diluted 
1:1000, while GAPDH was detected using the mouse monoclonal antibody clone 6C5 
(Millipore) diluted 1:2000. Primary antibodies were detected using peroxidase-
conjugated AffiniPure F(ab’)2 fragment goat anti-mouse or anti-rabbit IgG (H+L) 
(Jackson ImmunoResearch Laboratories, Inc.) diluted 1:5000 or peroxidase-conjugated 
AffiniPure F(ab’)2 fragment goat anti-rat IgG (H+L) (Jackson ImmunoResearch 
Laboratories, Inc.) diluted 1:10,000. 
Immunoblotting 
 Human beta cell lines were harvested and washed three times with DPBS. After 
a final spin, DPBS was aspirated, and cell pellets were stored at -80°C. Whole cell 
42 
lysates were prepared from pellets by lysing for 30 minutes on ice in 10 mM Tris-HCl pH 
6.8, 150 mM NaCl, and 1% Triton-X 100 containing 2X protease inhibitor cocktail 
(Sigma-Aldrich). When a phosphorylated protein was to be detected, 1X phosphatase 
inhibitor cocktail (Cell Signaling Technology) was also added to the lysis buffer. Debris 
and nuclei were pelleted by centrifuging for 10 minutes at 14,000 rpm at 4°C. Clarified 
lysates were transferred to clean microfuge tubes and placed on ice.  
 Protein concentrations were determined via microtiter protein assay (Bio-Rad) by 
interpolating absorbance at 570 nm into a known BSA standard curve (Pierce). Volumes 
of lysate containing 20-80 μg protein, depending on lysate concentration and well 
volume of stacking gel, were mixed with 5X reducing sample buffer and boiled 5 
minutes.  
Samples were loaded into gels and resolved by sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis for approximately 40 minutes at 60 mA using 8% or 
10% gels. Proteins were then transferred to 0.2 μm nitrocellulose membranes (GE 
Healthcare Life Sciences) for 60 minutes at 100 V at 4°C. Membranes were blocked for 
1 hour at room temperature or overnight at 4°C in a blocking buffer containing 5% milk in 
PBST. Incubations with primary antibodies diluted in blocking buffer were performed 
overnight at 4°C on a nutator. Alternatively, incubations with primary antibody to GAPDH 
were performed for 2 hours at room temperature.  
Membranes were washed 4 times for 5 minutes with tris-buffered saline 
containing 0.05% Tween-20 (TBST) and incubated with the proper secondary antibody 
for 30 minutes at room temperature. Streptactin-HRP (Bio-Rad) was also included to 
detect protein standards (Bio-Rad). Membranes were washed again, and proteins were 
detected with Luminata western HRP substrates (Millipore). 
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To determine relative protein expression levels, densitometry was performed 
using Fiji software (National Institutes of Health). Expression levels for experimental 
samples were normalized to that of the control sample. 
 As an internal control, levels of phospho-JNK and total JNK as well as phospho-
p38 and total p38 were visualized using the same membrane. After detection of 
phospho-proteins and loading controls, membranes were stripped for 20 minutes at 
55°C in 0.1 M Tris-HCl pH 7.4, 2% SDS, and 0.7% 2-mercaptoethanol. Membranes were 
washed twice in deionized water for 5 minutes and twice in TBST for 10 minutes and 
blocked as described above before incubation with the second primary antibody. 
Transfection of βLox5 Cells with Small Interfering RNA (siRNA) 
 βLox5 cells were grown in 12-well tissue culture plates in antibiotic-free βLox5 
medium to 90% confluency. Cells were then transfected with 100 nM control or 
SAPK/JNK siRNA (Cell Signaling Technology) for 72 hours using Lipofectamine 2000. 
Briefly, siRNA was diluted to 2 μM in antibiotic, serum, and BSA-free βLox5 medium in 
polystyrene tubes, while Lipofectamine 2000 was diluted to 80 μL/mL. These mixtures 
were vortexed gently and incubated for 6 minutes at room temperature. Equal volumes 
of siRNA and Lipofectamine 2000 were mixed together and incubated for 20 minutes at 
room temperature. Volumes of 100 μL siRNA/Lipofectamine 2000 were added dropwise 
to wells containing 900 μL antibiotic-free βLox5 medium and swirled gently. Wells 
contained a final concentration of 100 nM siRNA and 4 μL/mL Lipofectamine 2000. 
Media was replaced with fresh antibiotic-free βLox5 media after 24 hours, and cells were 
allowed to recover for 48 hours at 37°C. After this 72 hour transfection period, one well 
of control and JNK siRNA-treated cells were harvested, and protein knockdown was 
confirmed by immunoblotting. Media was aspirated from remaining wells, and cells were 
treated for 24 hours with media alone or cytokine cocktail. After 24 hours, media was 
harvested and stored at -20°C for ELISA.  
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 Mice 
 Five week-old female NOD/ShiLtJ (NOD) mice were purchased from the Jackson 
Laboratory and housed in a specific pathogen-free environment within the Indiana 
University School of Medicine Laboratory Animal Research Care Facility (Indianapolis, 
IN). Mice were allowed to acclimate for one week after shipping prior to the initiation of 
an experiment. All animal experiments were performed in accordance with protocols 
approved by the Indiana University School of Medicine Institutional Animal Care and Use 
Committee (Indianapolis, IN). 
Treatment with 17-DMAG 
 Six week-old female NOD mice were injected intraperitoneally every third day 
with PBS or 2 mg/kg 17-DMAG (InvivoGen) for 18 weeks (61).  The development of 
TIDM was monitored by measuring body weight and non-fasting blood glucose levels 
once per week. Mice were considered diabetic after two consecutive weekly blood 
glucose readings above 300 mg/dl. Blood glucose measurements were taken via tail 
bleed using a glucometer (Abbott). Moribund animals were sacrificed at approximately 
19 weeks of age, and pancreata were isolated for histology. Surviving animals were 
sacrificed at 21 and 24 weeks of age, and pancreatic islets were isolated for qRT-PCR. 
Collection of Serum 
Blood samples were collected from a cohort of PBS and 17-DMAG-treated mice 
once per week by facial bleed into Microvette CB 300 K2E non-heparinized tubes 
(Sarstedt). Serum was isolated by centrifugation and used for HSP90 ELISA. 
Histology 
 Pancreata from female NOD mice were fixed in formalin overnight and then 
placed in 70% ethanol for 24 hours. Histological sections were prepared and stained 
with hematoxylin and eosin by the Indiana University School of Medicine Histology Core 
(Indianapolis, IN). Insulitis was scored as previously described by a single observer (62). 
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Briefly, grade 1 = no mononuclear cell infiltrates associated with islets; grade 2 = peri-
insulitis affecting less than 50% of the islet circumference with no evidence of intra-islet 
invasion; grade 3 = peri-insulitis affecting greater that 50% of the islet circumference with 
no evidence of intra-islet invasion; grade 4 = invasion of mononuclear cells into islets. 
Statistics 
 For comparisons between two groups, statistical significance was determined 
using a two-tailed, unpaired t test. For qRT-PCR experiments in which two different 
treatments were tested on samples from the same individual human donor, a two-tailed, 
ratio paired t test was used. To determine statistical significance among three or more 
groups, a one-way analysis of variance (ANOVA) was used with Dunnett’s test to correct 
for multiple comparisons, each experimental mean being compared to the control mean. 
In experiments with two independent variables, statistical significance was determined 
using a two-way ANOVA with Tukey’s test to correct for multiple comparisons between 
groups. Survival curves were analyzed using a Mantel-Cox test. A p-value less than 0.05 
was considered statistically significant with *p < 0.05, **p < 0.01, ***p < 0.001, and ****p 
< 0.0001. Statistics were calculated using Prism 6.04 (GraphPad Software, Inc.). 
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RESULTS 
I. Pancreatic Beta Cell HSP90 Release in Response to Stress  
A. Effects of Cell Density on Beta Cell HSP90 Release 
 To investigate the effects of cellular stress on HSP90 release from pancreatic 
beta cells, two human pancreatic beta cell lines, βLox5 and 1.1B4, were used. βLox5 
cells were previously generated by retroviral transduction of adult beta cells with the 
floxed SV40 T antigen, Rasval12, and hTERT oncogenes (59). 1.1B4 cells were previously 
generated by electrofusion of adult cadaveric islet cells with the immortalized PANC-1 
epithelial cell line (60). As our lab had no prior experience growing these cells, 
preliminary optimization experiments were performed to determine the appropriate cell 
density at which to treat these cells with various stress-inducing stimuli. 
 βLox5 and 1.1B4 cells grown to medium and high density were treated with a 
cocktail of pro-inflammatory cytokines containing 5 ng/mL human recombinant IL-1β, 10 
ng/mL human recombinant TNF-α, and 100 ng/mL human recombinant IFN-γ for 24 
hours at 37°C. This combination of cytokines was chosen because it was found to 
produce the most cytotoxic effect, relative to other combinations of cytokines, in primary 
human cadaveric islets isolated from adult pancreata (63). Following treatment, 
supernatants were harvested, and levels of the alpha cytoplasmic isoform of HSP90 
were measured by ELISA. HSP90 release in response to cytokine stress was more 
pronounced in βLox5 and 1.1B4 cells when treated at high density (Figure 6 A-B). 
These results may be due to increased levels of stress in the more confluent cells. In 
light of these results and given that beta cells in vivo are tightly clustered within the islets 
of Langerhans, cells grown to high density were treated with stress-inducing stimuli in all 
subsequent experiments.  
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Figure 6. Human beta cell lines release more HSP90 in response to pro-
inflammatory cytokines when treated at high density. βLox5 (A) and 1.1B4 (B) cells 
grown to 60% or 90% confluency were treated with media alone (Ctrl) or a cytokine 
cocktail containing 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ (Cyt) for 24 
hours at 37°C. Culture supernatants were harvested, and HSP90 levels were assayed 
by ELISA. Data are mean + SEM from N=3 experiments. *p < 0.05 Two-tailed, unpaired t 
test. 
B. Beta Cell HSP90 Release in Response to Various Stressors 
As discussed previously, beta cell stress is a major factor that contributes to the 
development of TIDM, and several cellular stress events are known to be associated 
with these cells during the latent period of TIDM. For example, ER stress has been 
shown to precede the development of TIDM in NOD mice (64), and elements of ER 
stress are known to be upregulated in the islets of humans with TIDM (65). As beta cell 
mass starts to wane during this pre-clinical stage of disease, beta cells are particularly 
vulnerable to ER stress due to an increased demand for insulin production. 
Insulitis, the infiltration of immune cells into the islets of Langerhans prior to the 
onset of TIDM, is another source of beta cell stress. Treating beta cell lines with a 
cocktail of IL-1β, TNF-α, and IFN-γ is used to model insulitis in vitro. These cytokines are 
secreted by activated macrophages and T cells during insulitis and are known to 
contribute to beta cell ER stress, dysfunction, and death (66). 
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As beta cell mass decreases and insulin production is impaired, blood glucose 
levels rise. This condition, known as hyperglycemia,  is another source of beta cell stress 
during the latent period of TIDM (19). Because beta cells utilize the majority of 
glycolysis-generated pyruvate in the tricarboxylic acid cycle, which produces ROS, 
hyperglycemia results in increased ROS production by beta cells. These elevated levels 
of ROS can further exacerbate ER stress (19), possibly by altering Ca2+ levels in the ER 
(29). This condition is known as glucotoxicity. 
To test whether ER stress could result in HSP90 release from pancreatic beta 
cells, βLox5 and 1.1B4 cells were treated with thapsigargin, an inhibitor of SERCAs. 
Thapsigargin inhibits the transport of Ca2+ from the cytosol to the ER, resulting in the 
dysfunction of ER chaperones and the development of ER stress. To model insulitis, 
cells were again treated with a cocktail of pro-inflammatory cytokines containing IL-1β, 
TNF-α, and IFN-γ. To test whether glucotoxicity could result in HSP90 release from 
pancreatic beta cells, βLox5 and 1.1B4 cells were treated with culture media containing 
33.3 mM glucose. Interestingly both βLox5 and 1.1B4 cells released HSP90 in response 
to cytokine stress but not in response to thapsigargin or high glucose (Figure 7 A-B). 
These results suggest HSP90 may be released in response to cytokines independently 
of their ability to induce ER stress. 
To determine whether these results are also true for other species, this 
experiment was repeated with the murine insulinoma cell line MIN6. This cell line was 
originally developed from a transgenic mouse expressing the large SV40 T antigen in 
pancreatic beta cells and has been shown to exhibit characteristics of glucose 
metabolism and insulin secretion that are similar to those of normal islets (67). Contrary 
to what was observed with human beta cell lines, MIN6 cells released HSP90 in 
response to all three stimuli: thapsigargin, pro-inflammatory cytokines, and high glucose 
(Figure 7C). However, the strongest response was produced in response to cytokine 
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cocktail. These differences between MIN6 cells and the human beta cell lines could be 
due to the different species of origin. Indeed, pro-inflammatory cytokines have been 
shown to give rise to ER stress by different mechanisms in mouse, rat, and human beta 
cell lines (28), suggesting the stress responses in beta cells from these three species 
may be different. For these reasons, human beta cell lines were used as a model for the 
majority of experiments in this work. 
The ability of cytokine stress to promote HSP90 release in human beta cells was 
confirmed by treating primary human cadaveric islets with cytokine cocktail. Similarly to 
beta cell lines, primary human cadaveric islets also released HSP90 in response to 
cytokine stress (Figure 7D). 
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Figure 7. HSP90 is released by human beta cells in response to cytokine stress.  
Human beta cell lines βLox5 (A) and 1.1B4 (B) were treated for 24 hours at 37°C with 
media alone (Ctrl); 0.1 μM thapsigargin (Tg) to induce ER stress; a cytokine cocktail 
containing 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ (Cyt) to mimic insulitis; 
or culture media containing 33.3 mM glucose (Glc) to mimic glucotoxicity. Culture 
supernatants were harvested, and HSP90 levels were assayed by ELISA. The same 
experiment was performed in the murine MIN6 cell line (C) using recombinant murine 
cytokines. Results in A and B were confirmed by treating primary human cadaveric islets 
with human recombinant cytokine cocktail (D). Data are presented as relative to control. 
Actual values of HSP90 were detected between 0.7-4.9 ng/mL for βLox5, 0.9-6.4 ng/mL 
for 1.1B4, 0.3-19.9 ng/mL for MIN6, and 0.9-20.1 ng/mL for human islets. Data are mean 
+ SEM of N=3 experiments or N=9 islet donors. For cell line experiments *p <0.05, **p < 
0.01, ***p < 0.001 One-way ANOVA with Dunnett’s correction for multiple comparisons, 
each mean compared to control mean. For human islets, **p<0.05 Two-tailed, unpaired t 
test.  
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C. Mechanism of Release 
In vitro treatment with pro-inflammatory cytokines is known to result in apoptosis 
of human beta cell lines, particularly after 48 hours (28). However, in these experiments 
cells were treated with cytokines for a shorter 24 hour time period to avoid the possibility 
that HSP90 may passively leak out of cells as a result of increased cell membrane 
permeability following cell death. To confirm that stress treatments were not affecting cell 
viability, trypan blue exclusion was performed, and no differences in viability were 
observed in βLox5, 1.1B4, or primary human islet cells (Figure 8 A-C).  
To confirm these results, LDH cytotoxicity assays were performed in βLox5 cells. 
This colorimetric assay quantitatively measures the activity of LDH, a cytosolic enzyme, 
released non-specifically into culture media as a result of cell death. As in experiments 
with trypan blue, no changes in viability were observed in stressed βLox5 cells relative to 
the control sample (Figure 8 D). LDH assays of βLox5 cells treated with cytokines for 
various time points confirmed that significant cytotoxicity did not occur until 48 hours 
post-treatment (Figure 8E), thus confirming that HSP90 was not passively released as a 
result of cell death at earlier time points.  
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Figure 8. Human beta cell 24 hour stress treatments are not cytotoxic. βLox5, 
1.1B4, and human islets were treated as in Figure 7, and viability was determined by 
trypan blue exclusion (A-C). Results were confirmed in βLox5 cells by LDH assay (D). 
Here viability is calculated as percent relative to the control sample. βLox5 cells were 
treated with cytokine cocktail for various time points, and LDH assays were performed 
(E). Here viability for each time point is presented as a percent relative to control cells 
treated with media alone for the same amount of time. Data are mean + SEM of N=3 
experiments (A-B) and (D-E) or N=4 islet donors (C). ***p < 0.001 One-way ANOVA with 
Tukey’s correction for multiple comparisons. 
Although elevated levels of HSP90 were clearly released in response to cytokine 
stress in beta cells (Figure 7), the mechanism of release into the extracellular 
environment remained unclear. LDH assays suggested HSP90 was not passively 
released as a result of cell death (Figure 8).  
To further address this question, ELISAs for HSP70 and HSC70, two other 
cytosolic chaperone proteins, were performed on culture media from control and 
cytokine-treated βLox5 cells. No extracellular HSP70 or HSC70 was detected in either 
experiment, suggesting cytosolic proteins were not passively leaking from cells in 
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response to cytokine-mediated cell death (data not shown). Together the data presented 
here suggest HSP90 was released by an active secretory mechanism. 
Interestingly several studies have shown HSP90 is released in response to cell 
stress (53; 55; 58), and some studies have shown HSP90 is present in extracellular 
vesicles known as exosomes (68). Furthermore, HSP90-containing exosomes were 
found to be secreted by B cells in response to heat shock stress (51). Exosomes are 
known to play important roles in intercellular communication and biological signaling 
(52), and may even have implications for TIDM, as one study showed horizontal transfer 
of exosomal microRNAs could transfer apoptotic signals between beta cells (69). 
To determine whether beta cells release HSP90 in association with exosomes, a 
commercially available exosome-precipitation solution was used to isolate βLox5 
exosomes released after 24 hours of cytokine stress. These exosomes were lysed, and 
exosomal HSP90 levels were assayed by ELISA together with the soluble HSP90 levels 
present in supernatants following exosome precipitation. A good control experiment to 
pursue in the future would be to confirm exosome purity obtained with this solution using 
nanoparticle tracking analysis or immunoblotting for exosome markers such as CD63.  
Nevertheless, experiments here showed HSP90 levels were significantly 
increased in exosomes isolated from cytokine-treated βLox5 cells compared to control-
treated cells (Figure 9). In fact, the relative increase in exosomal HSP90 with cytokine 
stress was much greater than the increase in soluble HSP90 (≈eight-fold versus two-
fold). This result may indicate an increase in the quantity of exosomes released, or 
alternatively, it could signify a change in the protein content of beta cell exosomes during 
cytokine stress. Thus, exosomal HSP90 may be a more sensitive marker of beta cell 
stress than soluble HSP90.  
However, exosome isolation and analysis can be difficult with small volumes of 
biological fluids. Thus, exosomes represent a challenging source material for biomarker 
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analysis, particularly in children, who are the primary candidates for TIDM pre-screening. 
Therefore, we elected to continue to focus these studies on detection of soluble HSP90 
given our success in using this form of the chaperone in predicting TIDM onset in young 
children (31). 
 
Figure 9. HSP90 released from beta cells in response to cytokine stress is mostly 
soluble and not associated with exosomes. Exosome-free βLox5 media was 
prepared by ultracentrifugation and used to treat βLox5 cells for these experiments. 
βLox5 cells were treated with 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ for 
24 hours at 37°C. Media was collected and βLox5 exosomes were precipitated using a 
commercially available exosome precipitation solution. Exosomes were lysed and 
HSP90 levels were assayed by ELISA. HSP90 concentrations were multiplied by the 
final sample volume to give total HSP90 in ng. The soluble fraction is the supernatant left 
after exosome precipitation. Data are mean + SEM of N=3 experiments. **p < 0.01 Two-
tailed, unpaired t test.  
To determine whether IL-1β, TNF-α, or IFN-γ alone or whether some 
combination of these cytokines was responsible for HSP90 release, βLox5 cells were 
treated with all possible permutations of IL-1β, TNF-α, and IFN-γ for 24 hours at 37°C. 
Although IL-1β alone and each pair of cytokines induced a slight elevation in HSP90 
release relative to control-treated cells, by far the most robust release of HSP90 was 
H
SP
90
 (n
g)
55 
observed when cells were treated with all three cytokines (Figure 10). These results are 
consistent with previous studies showing this combination of cytokines induces the most 
stress in human islets (63). 
 
Figure 10. Beta cells optimally release HSP90 in response to a combination of IL-
1β, TNF-α, and IFN-γ. βLox5 cells were treated with 5 ng/mL IL-1β, 10 ng/mL TNF-α, 
and 100 ng/mL IFN-γ alone or in various combinations for 24 hours at 37°C. Media was 
harvested after incubation, and HSP90 levels were measured by ELISA. Data are 
presented as relative to control. Actual values of HSP90 were detected between 3.4-
30.9 ng/mL. Data are mean + SEM of N=3 experiments. **p<0.01 One-way ANOVA with 
Dunnett’s correction for multiple comparisons, each mean compared to no cytokine 
control. 
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To determine whether increased HSP90 release in response to cytokine stress 
was a result of changes in gene or protein expression, qRT-PCR and immunoblotting 
experiments were performed. Expression levels of HSP90AA1, which encodes the alpha 
cytoplasmic isoform of HSP90, were measured by qRT-PCR using samples from βLox5, 
1.1B4, and MIN6 cells treated with thapsigargin, cytokine cocktail, or high glucose for 6 
or 24 hours. No notable increases in HSP90AA1 expression levels were observed in 
these cell lines at either time point (Figure 11 A-F). These results suggest increased 
HSP90 release did not occur as a result of increased HSP90AA1 gene expression. 
These results were confirmed by performing qRT-PCR on samples from primary human 
cadaveric islets treated for 24 hours with cytokine cocktail (Figure 11 G).  
Detecting changes in HSP90AA1 gene expression in human islets is complicated 
by the presence of alpha cells and potentially other exocrine and endocrine cell types 
present in these structures. Thus, the current studies focused on relative changes in 
gene expression with cell stress rather than absolute values. Cellular stress can in some 
cases also alter housekeeping gene expression in cells, thus the current studies were 
analyzed by examining several endogenous genes as controls. For all human qRT-PCR 
studies in this work, GAPDH was ultimately used as an endogenous control for βLox5 
and 1.1B4 cells, while ACTB was used for primary human islets. 
To determine whether elevated levels of HSP90 were released in response to 
cytokine stress due to changes in protein level, we measured HSP90 levels by 
immunoblotting in βLox5 and 1.1B4 cells treated with cytokine cocktail for 24 hours. No 
increases in HSP90 protein level were observed in cytokine-treated βLox5 (Figure 12 A-
B) or 1.1B4 cells (Figure 12 B-D). In fact cytokine-treated βLox5 cells actually exhibited 
a slight but statistically significant decrease in HSP90 protein level (Figure 12 A-B). This 
result is consistent with cytoplasmic HSP90 being released from these cells. 
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Figure 11. Cytokine stress does not increase HSP90AA1 gene expression levels in 
beta cells. βLox5 (A), 1.1B4 (B), and MIN6 (C) cells were treated with for 6 hours with 
media alone (Ctrl); 1 μM thapsigargin (Tg); a cytokine cocktail containing 5 ng/mL IL-1β, 
10 ng/mL TNF-α, and 100 ng/mL IFN-γ (Cyt); or culture media containing 33.3 mM 
glucose (Glc) for 6 hours at 37°C. HSP90AA1 gene expression levels were measured by 
qRT-PCR. HSP90AA1 levels were also assayed in the same cell lines (D-F) as well as 
human islets (G) treated for 24 hours as in Figure 7. Data are mean + SEM of N=3 
experiments (A-F) or actual values for N=4 islet donors (G). *p < 0.05, **p < 0.01 One-
way ANOVA with Dunnett’s correction for multiple comparisons, each mean compared to 
the control mean.  
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D. Expression Levels of HSP90 Isoform Genes 
The relative abundance of multiple heat shock proteins can shift in response to 
distinct cell stressors. Thus, qRT-PCR experiments were performed to determine 
whether expression levels of other HSP90 isoform genes were increased with stress. No 
significant differences in HSP90AB1, which encodes the beta cytosolic isoform of 
HSP90, were observed in βLox5, 1.1B4, or MIN6 cells following 6 hours (Figure 13 A-C) 
or 24 hours (Figure 13 D-F) of incubation with thapsigargin, cytokine cocktail, or high 
glucose media.  
Levels of HSP90B1, which encodes the ER isoform of HSP90 GRP94, were 
significantly increased with thapsigargin treatment at both time points in all three cell 
lines examined (Figure 14 A-F). This result is expected given this gene is upregulated in 
response to ER stress and UPR activation (70).  
 Next, levels of TRAP1, which encodes the mitochondrial isoform of HSP90, were 
measured in βLox5, 1.1B4, and MIN6 cells treated with cytokine cocktail for 24 hours. 
No significant increases in TRAP1 expression were observed, again suggesting that 
cytokine stress did not induce upregulation of other HSP90 isoform genes (Figure 15 A-
C).  
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Figure 13. HSP90AB1 gene expression levels are unaltered in stressed beta cells. 
Beta cells were treated as described in Figure 11. Expression levels of HSP90AB1, 
which encodes the beta cytosolic isoform of HSP90, were measured by qRT-PCR at 6 
hours (A-C) and 24 hours (D-F) post-treatment. Data are mean + SEM of N=3 
experiments and were analyzed by one-way ANOVA with Dunnett’s correction for 
multiple comparisons, each mean compared to the control mean.  
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Figure 14. Thapsigargin treatment increases HSP90B1 gene expression levels in 
beta cells. Beta cells were treated as described in Figure 11. Expression levels of 
HSP90B1, which encodes the ER isoform of HSP90 GRP94, were measured by qRT-
PCR at 6 hours (A-C) and 24 hours (D-F) post-treatment. Data are mean + SEM of N=3 
experiments. *p < 0.05, ***p < 0.001, and ****p < 0.0001 One-way ANOVA with 
Dunnett’s correction for multiple comparisons, each mean compared to the control 
mean. 
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Figure 15. TRAP1 gene expression levels in beta cells treated with pro-
inflammatory cytokines. βLox5 (A), 1.1B4 (B), and MIN6 (C) cells were treated with 5 
ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ for 24 hours at 37°C. Following 
incubation, cell pellets were harvested for RNA extraction and cDNA synthesis. 
Expression levels of TRAP1, which encodes the mitochondrial isoform of HSP90, were 
measured by qRT-PCR. Data are mean + SEM of N=3 experiments. *p < 0.05 Two-
tailed, unpaired t test.  
Expression levels of HSP90AB1, HSP90B1, and TRAP1 were also measured in 
human islets treated with cytokine cocktail for 24 hours. Patterns of expression similar to 
those seen in βLox5 cells were observed. No significant differences in HSP90AB1 
expression were detected (Figure 13 D and Figure 16 A). HSP90B1 expression 
increased about two-fold in both βLox5 cells and primary islets treated with cytokine 
(Figure 14 D and Figure 16 B); however, the result seen in βLox5 cells was not 
statistically significant when compared to the robust response of the thapsigargin-treated 
cells. These results suggest this cytokine cocktail of IL-1β, TNF-α, and IFN-γ may be 
inducing ER stress in beta cells, but not to the extent that thapsigargin does. TRAP1 
levels were reduced by one-half in both βLox5 cells and primary islets (Figure 15 A and 
Figure 16 C). Taken together, the results of these qRT-PCR experiments suggest that of 
the cell lines tested, βLox5 cells respond to stress most similarly to primary islet cells. 
The relative increase in HSP90 release observed in βLox5 cells by ELISA was also the 
most similar to the HSP90 release observed with primary human islets (Figure 7 A and 
A. B. C. 
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D), approximately a two to three-fold increase. For these reasons, βLox5 cells were used 
as a model of pancreatic beta cell stress for the majority of experiments in this work. 
Figure 16. HSP90 isoform gene expression levels in primary islet cells treated with 
pro-inflammatory cytokines. Primary human cadaveric islets were treated with 5 
ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ for 24 hours at 37°C. Following 
incubation, cells were harvested for RNA isolation and cDNA synthesis. Expression 
levels of HSP90AB1 (A), HSP90B1 (B), and TRAP1 (C) were measured by qRT-PCR. 
Data are actual values for N=4 islet donors. *p < 0.05 Two-tailed, ratio paired t test. 
E. Beta Cell HSP90 Release in Response to TLR Stimulation 
Given HSP90 was released by beta cells in response to pro-inflammatory 
cytokines but not thapsigargin or high glucose (Figure 7) and that this change was not 
the result of decreased cell membrane integrity (Figure 8) or changes in gene or protein 
expression levels (Figures 11-12), we next hypothesized that HSP90 may be released 
as part of a unique cell-autonomous response to cytokine stress. 
 Cell-autonomous immunity is defined as the response of host cells, specifically 
non-immune cells, to invading infectious agents. Components of cell-autonomous 
immunity include antimicrobial proteins, specialized degradative compartments, and 
programmed host cell death. These responses are often initiated in response to 
pathogen sensing through PRRs and danger receptors (71; 72). Because so much 
crosstalk exists between TLR and pro-inflammatory cytokine signaling pathways (Figure 
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1), we wondered if HSP90 was being released in response to some form of cell-
autonomous innate immune signaling in beta cells. 
In one study involving murine cells, differential cell-autonomous responses in 
murine pancreatic alpha and beta cells were shown to determine the outcome of 
coxsackievirus infection. Alpha cells were able to induce a stronger STAT1-mediated 
antiviral response and thus thwart the deleterious effects of the virus more efficiently 
than beta cells. These authors postulated that less efficient beta cell-autonomous 
immune responses may play an important role in beta cell death, the initiation of insulitis, 
and ultimate progression to TIDM in response to viral infection (73).  
Mouse and human pancreatic islets have been reported to express TLR2, TLR3, 
TLR4, and TLR9, and TLR3 expression has been reported to increase with IL-1β and 
IFN-γ stimulation. Extracellular dsRNA derived from dying cells has even been shown to 
bind beta cell TLR3 and trigger apoptosis (26). Thus, beta cell-autonomous immune 
responses may be initiated through stimulation of these receptors. 
 Expression levels of TLR2, TLR3, TLR4, and TLR9 mRNA were measured by 
qRT-PCR in βLox5 and primary islet cells treated with media alone or IL-1β, TNF-α, and 
IFN-γ for 24 hours. Both βLox5 and primary islets expressed TLR2, TLR3, and TLR4, 
while no TLR9 was detected (Figure 17 A-B). Expression of TLR9 in islet cells reported 
in other studies may have been due to the presence of infiltrating immune cells. 
Expression levels of TLR2, TLR3, and TLR4 were similar in βLox5 cells and increased 
slightly with cytokine stimulation. However in primary islets, expression levels of TLR2 
and TLR3 were similar without cytokine stimulation and increased following treatment; 
however, TLR3 expression was most highly expressed with cytokine stimulation in 
primary islet cells (Figure 17 B). Expression levels of TLR4 in primary islet cells were 
lower than TLR2 and TLR3 (Figure 17 B). 
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Figure 17. TLR gene expression levels in βLox5 and primary human islet cells. 
βLox5 (A) and primary islet (B) cells were treated with media alone or 5 ng/mL IL-1β, 10 
ng/mL TNF-α, and 100 ng/mL IFN-γ for 24 hours at 37°C. Following incubation, cells 
were harvested for RNA isolation and cDNA synthesis. Expression levels of TLR2, 
TLR3, TLR4, and TLR9 were measured by qRT-PCR (UD, undetected). Data are mean 
+ SEM of N=3 experiments or N=3-4 islet donors. *p < 0.05, **p < 0.01 Multiple t tests 
with multiple comparisons corrected using the Sidak-Bonferroni method.  
In one study, TLR3 stimulation was found to induce diabetes in B6/RIP-B7.1 
mice, while stimulation of TLR2, TLR4, and TLR9 did not (74). Thus, to determine the 
effects of TLR stimulation on pancreatic beta cells, stress responses were measured in 
response to TLR3 and TLR4 stimulation. Human βLox5 cells were stimulated with PIC to 
stimulate TLR3 and LPS to stimulate TLR4 for 24 hours. As a positive control for cell 
activation by each TLR ligand, IL-6 levels were measured by ELISA, and both TLR3 and 
TLR4 stimulation resulted in similar levels of IL-6 production (Figure 18 A-B). 
Interestingly, however, elevated levels of HSP90 were released in response to TLR3 
stimulation with PIC, but not in response to TLR4 stimulation with LPS (Figure 18 C-D). 
PIC treatment was slightly cytotoxic to cells, while LPS was not (Figure 19 A-B). 
Additionally treatment with PIC or LPS did not alter gene expression levels of 
HSP90AA1 (Figure 19 C-D). 
 These results suggest TLR3 stimulation in response to a viral infection may be 
relatively more stressful and cytotoxic to pancreatic beta cells than TLR4 stimulation in 
A. B. 
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response to a bacterial infection. Thus these results may provide insight as to why viral 
infections might be associated with beta cell death and the development of TIDM. 
 
Figure 18. Beta cells release HSP90 in response to TLR3, but not TLR4 
stimulation. Human βLox5 cells were transfected with 0.1 μg/mL PIC in Lipofectamine 
2000 to stimulate TLR3 (A and C) and treated with media containing 1 μg/mL LPS to 
stimulate TLR4 (B and D) for 24 hours at 37°C. For PIC stimulation, cells were treated 
with βLox5 media containing Lipofectamine 2000 alone as a control. For LPS 
stimulation, cells were treated with βLox5 media alone as a control. After incubation, 
culture media was harvested and IL-6 (A-B) and HSP90 (C-D) levels were assayed by 
ELISA. For HSP90 ELISAs, data are presented as relative to control. Actual values were 
detected between 8.9-84.4 ng/mL for PIC experiments and 10.0-52.2 ng/mL for LPS 
experiments. Data are mean + SEM of N=3 experiments. *p < 0.05, ****p < 0.0001 Two-
tailed, unpaired t test (ns, not significant).   
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Figure 19. Beta cell viability and HSP90AA1 gene expression levels in response to 
TLR3 and TLR4 stimulation. Human βLox5 cells were treated with PIC and LPS as 
described in Figure 18. LDH assays were performed with culture supernatants (A-B). 
Data are presented as percent viability relative to control samples. Cells were also 
harvested after treatment for RNA isolation and cDNA synthesis. Expression levels of 
HSP90AA1 were measured by qRT-PCR (C-D). Data are mean + SEM of N=3 
experiments. *p < 0.05 Two-tailed, unpaired t test. 
Thus far, results of these studies have shown that pancreatic beta cells release 
HSP90 in response to stimulation with a cocktail of pro-inflammatory cytokines 
containing IL-1β, TNF-α, and IFN-γ as well as TLR3 stimulation with PIC. However, 
human beta cells do not release HSP90 in response to stimulation with thapsigargin, 
high glucose media, or LPS. HSP90 release was not associated with dramatic 
decreases in cell viability or changes in HSP90 gene or protein expression levels. Thus, 
these results suggest HSP90 may be actively released in response to a specific innate 
immune stress in these cells, which may possibly occur in vivo during the pre-clinical 
latent period of TIDM, thus supporting a role for this protein as a biomarker of latent 
TIDM. Our next aim for this work was to understand the intracellular signaling events 
that contribute to cytokine- and PIC-induced HSP90 release from beta cells. 
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II. Beta Cell HSP90 Release and Oxidative Stress 
A. Beta Cell Cytokine Stress and iNOS Activity 
 Although pro-inflammatory cytokines have been shown to induce ER stress in 
pancreatic beta cells (28; 66), here HSP90 was not released by beta cells in response to 
thapsigargin, a SERCA inhibitor that induces ER-stress (Figure 7). Thus, we 
hypothesized that some other stress response induced in response to cytokines may 
contribute to HSP90 release in pancreatic beta cells, rather than ER stress.  
In rat beta cells, pro-inflammatory cytokine stimulation was shown to result in 
production of the RNS NO. In this study, NO production downregulated SERCA2b 
expression and resulted in the depletion of ER Ca2+ stores, development ER stress, and 
subsequent cell death (27). NO can be produced by the enzyme iNOS, which is encoded 
by the gene NOS2. Here, 24 hour cytokine stress was shown to induce expression of 
NOS2 in βLox5, MIN6, and primary human islets (Figure 20 A-C). However, expression 
of NOS2 was not induced in response to cytokine stress in 1.1B4 cells (data not shown). 
This difference could be due to the fact that 1.1B4 is an islet-epithelial fusion cell line 
(60). 
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Figure 20. Expression levels of NOS2 in pancreatic beta cells treated with pro-
inflammatory cytokines. βLox5 (A), MIN6 (B), and primary human islet cells (C) were 
treated for 24 hours at 37°C with media alone (Ctrl) or a cytokine cocktail containing 5 
ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ (Cyt). Following incubation cells 
were harvested for RNA isolation and cDNA synthesis, and NOS2 expression was 
measured by qRT-PCR (UD, undetected). Data are mean + SEM of N=3 experiments 
(A-B) or actual values of N=4 islet donors (C).  
Given that HSP90 has been shown to be released from vascular smooth muscle 
cells in response to oxidative stress (53) and that NOS2 was shown to be induced by 
pro-inflammatory cytokines in pancreatic beta cells in our studies, we hypothesized that 
HSP90 may be released in response to NO production in these cells. To determine 
whether or not NO production was required for HSP90 release in response to cytokine 
stress, βLox5 cells were pre-treated for 6 hours with 1400W, an iNOS inhibitor, prior to 
24 hour stress treatment with IL-1β, TNF-α, and IFN-γ. HSP90 levels were then 
measured by ELISA, while viability was measured by LDH assay. Pre-treatment with 
1400W did not affect HSP90 release in response to cytokine stress in βLox5 cells 
(Figure 21 A). Additionally, no difference in viability was observed by LDH assay in 
βLox5 cells treated with cytokine and 1400W compared to cells treated with cytokine 
alone (Figure 21 B). Together these results suggest that production of NO is not 
A. B. C. 
Ctrl Cyt
0.0
0.5
1.0
1.5
2.0
2.5
Lox5
UD
Ctrl Cyt
0
5
10
15
Human Islets
UD
70 
required for HSP90 release in these cells. Indeed the expression levels of NOS2 in 
βLox5 cells and primary islets in response to cytokine stress shown in Figure 20 were 
relatively low (approximate CT = 32 in both cell types). 
Figure 21. Pharmacological inhibition of iNOS does not affect beta cell HSP90 
release or viability in response to cytokine stress. βLox5 cells were treated for 6 
hours at 37°C with media alone or 100 μM 1400W followed by 24 hour stimulation with 5 
ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ. Following incubation, media was 
harvested, and HSP90 levels were detected by ELISA (A). Data are presented as 
relative to control cells without 1400W. Actual values of HSP90 were detected between 
10.0-34.6 ng/mL. Cell viability in response to treatment was determined by LDH assay 
(B). Data are presented as percent viability relative to control cells without 1400W. Data 
are mean + SEM of N=3 experiments. *p < 0.05 Two-way ANOVA with Tukey’s 
correction for multiple comparisons (ns, not significant). 
B. Beta Cell Cytokine Stress and HIF-1α Activity 
Although NO production was found to be dispensable for HSP90 release in 
response to cytokine stress, some other source of oxidative stress could be contributing 
to HSP90 release in human beta cells. Interestingly, some studies have shown that 
activity of the transcription factor HIF-1α can be regulated by oxidative stress (75). 
Usually under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylase 
(PHD) enzymes. This hydroxylation targets HIF-1α for polyubiquitination and 
degradation by the proteasome. However under hypoxic conditions, HIF-1α is not 
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We hypothesized that increased oxidative stress and HIF-1α activity may 
promote HSP90 release from beta cells. This hypothesis was based on a recent study 
using human fibroblast cells which demonstrated that hypoxia can induce secretion of 
HSP90 through the activation HIF-1α and that secreted HSP90 is important for 
promoting fibroblast motility and wound healing (55). However, how a transcription factor 
such as HIF-1α could promote secretion of HSP90 is currently unclear. In the present 
study, HIF1A expression was upregulated in response to 24 hour treatment with IL-1β, 
TNF-α, and IFN-γ in βLox5 and 1.1B4 cells (Figure 23 A-B) as well as primary islet cells 
from three of four donors (Figure 23 C). This change was not observed in MIN6 cells 
(Figure 23 D), but this discrepancy may be due to inter-species differences. 
These results are not surprising given HIF1A is a target of NF-κB and thus would 
be expected to increase in response to in vitro stimulation with pro-inflammatory 
cytokines. Sites of tissue inflammation, induced in response to infection or autoimmunity, 
are generally hypoxic and contain a high concentration of free oxygen radicals. Thus, the 
HIF-1α transcriptional program is often induced at these sites in vivo. For example, 
evidence of HIF-1α activation has been observed in affected tissues from patients with 
inflammatory disorders such as rheumatoid arthritis. Furthermore, HIF-1α has been 
shown to promote the production of pro-inflammatory cytokines by dendritic cells (77). 
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Figure 23. HIF1A gene expression levels in beta cells treated with pro-
inflammatory cytokines. βLox5 (A), 1.1B4 (B), primary human islet (C), and MIN6 (D) 
cells were treated with media alone (Ctrl) or with 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 
100 ng/mL IFN-γ (Cyt) for 24 hours at 37°C. Following incubation, cells were harvested 
for RNA isolation and cDNA synthesis. Expression levels of HIF1A were measured by 
qRT-PCR. Data are mean + SEM of N=3 experiments or actual values from N=4 islet 
donors. For cell line data in panels A, B, and D, *p < 0.05 Two-tailed, unpaired t test. 
Human islet data in panel C were analyzed by two-tailed, ratio paired t test. 
To determine whether HIF-1α transcriptional activity was induced in pancreatic 
beta cells in response to cytokine stress, expression levels of VEGFA and CA9, two HIF-
1α target genes, were examined. VEGFA and CA9 expression levels were significantly 
increased in βLox5 cells in response to cytokine stress (Figure 24 A-B). However, 
VEGFA was not increased in 1.1B4 cells (Figure 24 C), while CA9 was not detected in 
this cell line (data not shown). VEGFA expression was increased in three of 4 islet 
donors (Figure 24 D); however, CA9 was not detected in these cells (data not shown). 
These results suggest HIF-1α may be more transcriptionally active in βLox5 and human 
islet cells than in 1.1B4 cells. 
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Figure 24. Beta cell HIF-1α target gene expression in response treatment with pro-
inflammatory cytokines. βLox5 (A-B), 1.1B4 (C), and primary human islet (D) cells 
were treated with media alone (Ctrl) or 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL 
IFN-γ (Cyt) for 24 hours at 37°C. Following incubation, cells were harvested for RNA 
isolation and cDNA synthesis. Expression levels of VEGFA and CA9 were measured by 
qRT-PCR. Data are mean + SEM of N=3-4 experiments or individual values from N=4 
islet donors. For cell line data in panels A-C, *p < 0.05 Two-tailed, unpaired t test. 
Human islet data in panel D were analyzed by two-tailed, ratio paired t test. 
To determine whether or not HIF-1α activity is required for HSP90 release in 
response to cytokine stress in pancreatic beta cells, βLox5 cells were pre-treated with 
chetomin, a HIF-1α inhibitor, for 6 hours prior to 24 hour stimulation with IL-1β, TNF-α, 
and IFN-γ. Following incubation, cell pellets were harvested for RNA isolation and cDNA 
synthesis, and culture media was harvested for LDH assay and HSP90 ELISA. To 
determine whether or not chetomin treatment was effective, expression levels of the HIF-
1α target CA9 were measured by qRT-PCR. Pre-treatment with chetomin decreased 
expression levels of CA9 in cytokine-treated cells back to control levels, suggesting HIF-
1α activity was inhibited with this drug (Figure 25 A). However, contrary to our 
hypothesis, HIF-1α inhibition further increased HSP90 release relative to control cells 
(Figure 25 B).  
LDH assays revealed that the difference in viability between cytokine-treated 
cells with and without chetomin was not statistically significant (Figure 25 C). We next 
examined expression levels of stress-associated genes in order to determine whether 
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chetomin treatment resulted in increased beta cell stress. These studies revealed that 
pre-treatment with chetomin increased expression levels of HSP90AA1 and NOS2 in 
cytokine-treated cells (Figure 26 A-B), suggesting that pre-treatment with chetomin may 
be placing additional stress on beta cells. Taken together, these results suggest HIF-1α 
activity is not required for HSP90 release in pancreatic beta cells in response to cytokine 
stress, and perhaps, HIF-1α activity may be important for mitigating stress responses in 
cytokine-treated beta cells. 
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Figure 25. HIF-1α activity is not required for HSP90 release in pancreatic beta cells 
in response to treatment with pro-inflammatory cytokines. βLox5 cells were treated 
with media alone or 10 nM chetomin for 6 hours at 37°C followed by 24 hour stimulation 
with 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ. Following incubation, cell 
pellets were harvested for RNA isolation and cDNA synthesis, while media was 
harvested for LDH assay and HSP90 ELISA. Expression levels of CA9 were measured 
by qRT-PCR (A). HSP90 levels were measured by ELISA (B). Data are presented as 
relative to control cells without chetomin. Actual values were detected between 1.4-46.5 
ng/mL. Cell viability was measured by LDH assay (C). Data are presented as percent 
viability relative to control cells without chetomin. Data are mean + SEM of N=3-4 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 Two-way ANOVA with Tukey’s 
correction for multiple comparisons (ns, not significant). 
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Figure 26. Effects of HIF-1α pharmacological inhibition and pro-inflammatory 
cytokine treatment on HSP90AA1 and NOS2 gene expression levels in pancreatic 
beta cells. Human βLox5 cells were treated as in Figure 25. Following incubation, cell 
pellets were harvested for RNA isolation and cDNA synthesis. Expression levels of 
HSP90AA1 and NOS2 were measured by qRT-PCR (A-B) (UD, undetected). Data are 
mean + SEM of N=3 experiments. *p < 0.05, ***p < 0.001, ***p < 0.0001 Two-way 
ANOVA with Tukey’s correction for multiple comparisons. 
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To confirm that HIF-1α activity was not required for HSP90 release from 
pancreatic beta cells in response to cytokine stress, βLox5 cells were pre-treated with 
DMOG for 6 hours prior to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. DMOG is a 
prolyl hydroxylase inhibitor and thus functions as a pharmacological stabilizer of HIF-1α. 
Following incubation, cell pellets were harvested for RNA isolation and cDNA synthesis, 
while media was harvested for HSP90 ELISA. LDH assays were also performed. To 
determine whether or not DMOG treatment was effective, expression levels of CA9 were 
monitored by qRT-PCR. Expression levels of CA9 were increased in both control and 
cytokine-treated cells that had been pre-treated with DMOG, suggesting this drug was 
effective at the concentration used (Figure 27 A).  
However, pre-treatment with DMOG did not significantly affect HSP90 release in 
control or cytokine-treated cells. HSP90 release in response to DMOG plus cytokine 
stress was slightly increased compared to the release observed in cells treated with 
cytokine alone, relative to control cells without DMOG (Figure 27 B). However, similar 
changes were observed by LDH assay, suggesting the slight increase observed in 
HSP90 release in cytokine-treated cells with DMOG may relate to cytotoxicity (Figure 27 
C). Overall, these results are consistent with those presented in Figure 25. Especially 
given that DMOG had no effect on HSP90 release in the control-treated cells, the results 
presented here suggest that increased HIF-1α activity does not result in increased 
HSP90 release from pancreatic beta cells. 
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Figure 27. HIF-1α stabilization does not promote HSP90 release from beta cells. 
βLox5 cells were pre-treated with media alone or 100 μM DMOG for 6 hours at 37°C 
prior to 24 stimulation with 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ. 
Following incubation, cell pellets were harvested for RNA isolation and cDNA synthesis. 
Expression levels of CA9 were measured by qRT-PCR (A). Media was also harvested, 
and HSP90 levels were measured by ELISA (B). Data are presented as relative to 
control cells without DMOG. Actual values of HSP90 were detected between 3.0-23.9 
ng/mL. Cell viability was also assessed by LDH assay (C). Here data are presented as 
percent viability relative to control cells without DMOG. Data are mean + SEM from N=2-
3 experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Two-way ANOVA with 
Tukey’s correction for multiple comparisons (ns, not significant). 
C. Beta Cell HSP90 Release in Response to Cytokine Stress and NAC 
To rule out a more general role for oxidative stress in promoting HSP90 release 
in pancreatic beta cells in response to cytokine stress, beta cells were treated with the 
antioxidant NAC prior to cytokine stress. Human βLox5 cells were treated for 6 hours 
with media alone, 0.2 mM, or 1 mM NAC for 6 hours at 37°C prior to 24 hour stimulation 
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with IL-1β, TNF-α, and IFN-γ. Following incubation, media was harvested for HSP90 
ELISA and LDH assay. Interestingly, while 0.2 mM NAC had no effect on HSP90 
release, pre-treatment with 1 mM NAC resulted in increased HSP90 release in both 
control and cytokine-treated cells (Figure 28 A). Meanwhile no changes in viability were 
observed by LDH assay (Figure 28 B). These results suggest that scavenging cellular 
ROS does not appear to inhibit HSP90 release. Yet unexpectedly, the use of a strong 
reductant to promote a redox shift within the environment of the cell did promote HSP90 
release. 
 
Figure 28. Effects of NAC on HSP90 release and viability in beta cells treated with 
pro-inflammatory cytokines. βLox5 cells were pre-treated with media alone, 0.2 mM, 
or 1 mM NAC for 6 hours at 37°C prior to 24 stimulation with 5 ng/mL IL-1β, 10 ng/mL 
TNF-α, and 100 ng/mL IFN-γ. Following incubation, media was harvested, and HSP90 
levels were measured by ELISA (A). Data are presented as relative to control cells 
without NAC. Actual values of HSP90 were detected between 15.5-44.4 ng/mL. Cell 
viability was also assessed by LDH assay (B). Here data are presented as percent 
viability relative to control cells without NAC. Data are mean + SEM from N=3 
experiments. *p < 0.05, ***p < 0.001, Two-way ANOVA with Tukey’s correction for 
multiple comparisons.  
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Although expression levels of NOS2 were increased in cytokine-treated beta 
cells, results of these studies suggest iNOS activity is not required for HSP90 release 
from pancreatic beta cells, as inhibition of iNOS with 1400W had no effect on HSP90 
release in beta cells treated with IL-1β, TNF-α, and IFN-γ. Additionally, these results do 
not support a role for oxidative stress-induced HIF-1α activity in HSP90 release from 
beta cells in response to treatment with pro-inflammatory cytokines. Although HIF1A and 
HIF-1α-dependent gene expression levels were increased in beta cells treated with IL-
1β, TNF-α, and IFN-γ, chetomin, a HIF-1α inhibitor, did not prevent HSP90 release from 
beta cells treated with these cytokines. Similarly, stabilization of HIF-1α with DMOG did 
not promote HSP90 release from beta cells. Experiments with the potent reductant NAC, 
however, suggest that the overall redox environment in the cell may impact the 
propensity of beta cells to release HSP90. The reducing micro-environment within the 
ER is important for protein folding and induction of the UPR. In light of this information, 
we decided to revisit the possibility that HSP90 release may be related to cytokine-
induced ER stress.  
III. Beta Cell HSP90 Release in Response to JNK Activation  
A. Expression Levels of UPR Markers in Stressed Beta Cells 
To determine whether or not ER stress plays a role in HSP90 release by beta 
cells, expression levels of five ER stress-associated genes, XBP1s, ATF4, ATF3, DDIT3, 
and HSPA5, were examined in cells treated with cytokine cocktail or PIC, the two stimuli 
shown to induce pancreatic beta cell HSP90 release in these studies. As a positive 
control, expression levels of ER stress-associated genes were examined in cells treated 
with thapsigargin. Additionally, expression levels of ER stress-associated genes were 
examined in LPS-treated beta cells.  
 As part of the UPR, XBP1s is activated downstream of IRE1 signaling, while 
ATF4 is activated downstream of PERK signaling. ATF3 expression is induced by ATF4 
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transcriptional activity (24). DDIT3 and HSPA5, which encode CHOP and BiP, 
respectively, are induced downstream of ATF6 signaling, although DDIT3 can also be 
induced by ATF4 (Figure 4) (23; 24). 
 In βLox5 cells, 24 hour stimulation with IL-1β, TNF-α, and IFN-γ resulted in a 
modest increase in the expression levels of XBP1s and ATF3 relative to control; 
however, these results were not significant when compared to the more robust 
responses of thapsigargin-treated cells (Figure 29 A, C). A similar result was observed 
previously with HSP90B1 expression (Figure 14 D). No differences were observed, 
however, in expression levels of ATF4, DDIT3, and HSPA5 (Figure 29 B, D-E). 
Together, these results suggest that cytokine stress may induce a mild or non-canonical 
ER stress in pancreatic beta cells after 24 hours of stimulation. Others have shown, 
however, that these transcripts can be induced to a greater extent in human pancreatic 
beta cells after 48 hours of cytokine stress (28). Thus, full induction of an ER stress 
response may require longer incubation times with pro-inflammatory cytokines. The 
current analysis focused on the first 24 hours after cytokine exposure, as cell death was 
minimal compared to 48 hours (Figure 8).  
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Figure 29. UPR gene expression in beta cells treated with thapsigargin and pro-
inflammatory cytokines. Human βLox5 cells were treated with media alone (Ctrl), 0.1 
μM thapsigargin (Tg), or 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ (Cyt) for 
24 hours at 37°C. Following incubation cells were harvested for RNA isolation and cDNA 
synthesis. Expression levels of the following ER stress markers were measured by qRT-
PCR: XBP1s, ATF4, ATF3, DDIT3 (CHOP), and HSPA5 (BiP). Data are mean + SEM of 
N=3 experiments. *p < 0.05, **p < 0.01, ****p < 0.0001 One-way ANOVA with Dunnett’s 
correction for multiple comparisons, each mean compared to control. 
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In human islets, 24 hour stimulation with IL-1β, TNF-α, and IFN-γ did not result in 
substantial changes in XBP1s or ATF4 expression in three of four donors. In one donor, 
expression of these genes increased (Figure 30 A-B). All four donors, however, showed 
increased expression of ATF3 with cytokine stimulation (Figure 30 C). Modest increases 
in DDIT3 and HSPA5 expression were observed in two of four donors for DDIT3 (Figure 
30 D) and three of four donors for HSPA5 (Figure 30 E). More substantial increases in 
expression levels of these genes were observed in the fourth donor (Figure 30 D-E). 
These results suggest that ER stress may be induced to different degrees in human 
islets in response to cytokine stress, depending on the donor. Again, full induction of ER 
stress may require more than 24 hours of stimulation with cytokines.  
One interesting observation is that ATF3 expression was induced in response to 
cytokine stress in βLox5 and primary islet cells, but not ATF4. This result may be 
explained by the fact that PERK signaling directly results in ATF4 translation (Figure 4), 
rather than ATF4 transcription. Thus, ATF3 transcription may be induced before ATF4 
transcription. Interestingly, ATF3 has been shown to negatively regulate transcription of 
IL6 and other NF-κB target genes (25). Furthermore, transcription of ATF3 can be 
upregulated by increased levels of ROS, as the ROS-sensitive transcription factor NRF2 
can also induce ATF3 expression (78). Thus, ATF3 expression may be induced by ER 
stress as well as other cellular stress events that elevate ROS as a mechanism to 
negatively regulate inflammation. 
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Figure 30. UPR gene expression in primary human cadaveric islets treated with 
pro-inflammatory cytokines. Primary human cadaveric islets were treated with media 
alone (Ctrl) or 5 ng/mL IL-1β, 10 ng/mL TNF-α, and 100 ng/mL IFN-γ (Cyt) for 24 hours 
at 37°C. Following incubation cell pellets were harvested for RNA isolation and cDNA 
synthesis. Expression levels of XBP1s (A), ATF4 (B), ATF3 (C), DDIT3 (D), and HSPA5 
(E) were measured by qRT-PCR. Data are actual values from N=4 islet donors. Data 
were compared by two-tailed, ratio paired t test. 
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Stimulation of beta cells with PIC resulted in increased expression of all five ER 
stress-associated genes (Figure 31 A-E). These results are consistent with previous 
studies in primary rat beta cells showing PIC transfection results in the induction of ER 
stress markers in these cells (79). However, the increases were less robust than those 
observed with thapsigargin (Figure 29). LPS stimulation had no marked effect on ER 
stress marker expression in βLox5 cells, although modest increases in XBP1s and ATF3 
expression were observed (Figure 31 F-J). 
Taken together, these results suggest 24 hour stimulation with IL-1β, TNF-α, and 
IFN-γ may induce a mild or non-canonical form of ER stress in pancreatic beta cells. 
PIC, however, induces a response more reminiscent of traditional ER stress. 
 
Figure 31. UPR gene expression in pancreatic beta cells treated with PIC and LPS. 
Human βLox5 cells were treated with PIC (A-E) or LPS (F-J) for 24 hours as described 
in Figure 18. Following incubation cells were harvested for RNA isolation and cDNA 
synthesis. Expression levels of XBP1s, ATF4, ATF3, DDIT3, and HSPA5 were 
measured by qRT-PCR. Data are mean + SEM of N=3 experiments. *p < 0.05, **p < 
0.01 Two-tailed, unpaired t test.  
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B. Effects of TUDCA on Beta Cell Stress  
Since some increases in ER stress marker expression were observed in 
pancreatic beta cells in response to cytokine stress, we hypothesized that ER stress 
may be contributing to HSP90 release in these cells. To test this hypothesis, βLox5 cells 
were pre-treated for 6 hours with TUDCA prior to 24 hour stimulation with IL-1β, TNF-α, 
and IFN-γ or PIC. TUDCA is a bile acid that functions as a chemical chaperone and 
helps restore homeostasis during ER stress. Although humans naturally express very 
low levels of this bile acid, hibernating animals such as black bears express very high 
levels of TUDCA, and black bear bile has been used in traditional Chinese medicine for 
over three millennia (80). Studies have shown that this compound has potent anti-
apoptotic effects, and it has been used successfully in the clinic to treat a variety of liver 
diseases (80; 81). In one study, administration of TUDCA during the pre-diabetic stage 
of TIDM dramatically reduced diabetes incidence in two mouse models of disease (82). 
 Here, pre-treatment with TUDCA substantially inhibited HSP90 release in βLox5 
cells in response to cytokine stress (Figure 32 A) and partially blocked HSP90 release 
in response to PIC stimulation (Figure 32 B). TUDCA did not improve cell viability in 
response to cytokine stress as measured by LDH assay (Figure 32 C); however, 
TUDCA pre-treatment slightly preserved viability in response to PIC stimulation (Figure 
32 D). Thus, the protective effects of TUDCA may differ mechanistically in cytokine and 
PIC-treated cells.  
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Figure 32. TUDCA inhibits HSP90 release in pancreatic beta cells treated with pro-
inflammatory cytokines or PIC. Human βLox5 cells were treated with media alone, 0.2 
mM, or 1 mM TUDCA for 6 hours at 37°C prior to 24 hour stimulation with cytokine 
cocktail or PIC as described in Figures 7 and 18, respectively. Following incubation, 
media was harvested and HSP90 ELISAs (A-B) and LDH assays (C-D) were performed. 
Data are mean + SEM of N=3-4 experiments. HSP90 ELISA data are presented as 
relative to control cells without TUDCA. Actual values were detected between 5.0-20.5 
ng/mL for panel A and 4.0-51.7 ng/mL for panel B. LDH data are presented as percent 
viability relative to control cells without TUDCA. *p < 0.05, **p < 0.01, ***p < 0.001 Two-
way ANOVA with Tukey’s correction for multiple comparisons (ns, not significant). 
In support of the conclusion that the protective effects of TUDCA may differ 
mechanistically in cytokine and PIC-treated cells, TUDCA did not inhibit IL-6 production 
in βLox5 cells treated with cytokine cocktail (Figure 33 A); however, pre-treatment with 
TUDCA partially inhibited IL-6 production in βLox5 cells treated with PIC (Figure 33 B). 
These results are consistent with the fact that PIC treatment resulted in a more 
traditional ER stress response than treatment with pro-inflammatory cytokines (Figures 
29 and 31). ER stress has been shown in several studies to promote NF-κB activation 
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through all three branches of the UPR (83). Thus, in PIC-stimulated beta cells, a portion 
of IL-6 may be produced in response to NF-κB activation mediated by the UPR. This IL-6 
production can be inhibited by TUDCA, which alleviates ER stress (Figure 33 B). 
Alternatively, this slight reduction in IL-6 production observed in the PIC-stimulated 
βLox5 cells pre-treated with TUDCA may not be biologically meaningful.  
Since cytokine treatment does not promote a robust activation of the UPR 
(Figure 29), IL-6 production in response to cytokine treatment is likely driven largely by 
activation of AP-1 and NF-κB downstream of pro-inflammatory cytokine receptor 
activation, and this activation is not inhibited by TUDCA (Figure 33 A). Nevertheless, 
given that some components of the UPR seem to be activated in response to pro-
inflammatory cytokine stimulation and that TUDCA can inhibit HSP90 release in 
response to cytokine-mediated stress, ER stress likely plays some role in HSP90 
release from pancreatic beta cells in response to pro-inflammatory cytokines. 
Figure 33. TUDCA partially inhibits IL-6 release in beta cells treated with PIC. 
Human βLox5 cells were treated as in Figure 32. Following incubation, media was 
harvested and IL-6 ELISAs (A-B) were performed. Data are mean + SEM of N=3-4 
experiments. ***p < 0.001, ****p < 0.0001 Two-way ANOVA with Tukey’s correction for 
multiple comparisons. 
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 To determine the signaling events promoting HSP90 release in response to 
stimulation with pro-inflammatory cytokines, expression patterns of beta cell stress-
associated genes were examined to determine which genes, upregulated in response to 
cytokine stress, could be modulated by TUDCA. In βLox5 cells, TUDCA partially blocked 
upregulation of the NF-κB and IRF target NOS2 (Figure 34 A), as well as the ER stress 
marker ATF3 (Figure 34 B). These genes were also upregulated with cytokine stress in 
human islets (Figure 20 C and Figure 30 C). Upregulation of the ER stress marker 
XBP1s and the pro-inflammatory cytokine IL6 were slightly blocked with 1 mM TUDCA, 
although not significantly (Figure 34 C-D). Expression of XBP1s was only upregulated in 
two of four islet donors in response to cytokine stress (Figure 30 A). Expression levels 
of other stress associated markers examined in this work thus far, including HSP90AA1, 
HIF1A, CA9, and VEGFA were not altered by pre-treatment with TUDCA in cytokine-
treated cells (data not shown). 
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Figure 34. Pre-treatment with TUDCA modulates the upregulation of specific 
cytokine-induced genes in pancreatic beta cells. Human βLox5 cells were treated 
with media alone, 0.2 mM, or 1 mM TUDCA for 6 hours at 37°C prior to 24 hour 
stimulation with IL-1β, TNF-α, and IFN-γ. Following incubation, cells were harvested for 
RNA isolation and cDNA synthesis. Gene expression levels of NOS2 (A), ATF3 (B), 
XBP1s (C), and IL6 (D) were analyzed by qRT-PCR (UD, undetected). Data are mean + 
SEM of N=3 experiments. ***p < 0.001, ****p < 0.0001 Two-way ANOVA with Tukey’s 
correction for multiple comparisons.  
Interestingly, several IFN regulated genes were upregulated in response to 
cytokine stress in beta cell lines (Figure 35 A-C). TUDCA significantly blocked 
upregulation of the interferon-stimulated genes ISG15 and IFI27 (Figure 35 A-B); 
however, pre-treatment with TUDCA did not significantly affect upregulation of the 
interferon-regulated gene B2M (Figure 35 C), suggesting the inhibitory effects of 
TUDCA are gene-specific rather than global. ISG15, IFI27, and B2M were also 
upregulated in primary islet cells in response to cytokine stress (Figure 36 A-C).  
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ISG15 is a 17 kDa protein induced in response to type I IFN signaling, pathogen 
infection, and cellular stress. Free ISG15 can be secreted from cells where it functions 
as both cytokine and chemokine. Alternatively, ISG15 can be conjugated to other 
proteins in a process termed ISGylation, which is similar to ubiquitination. Although a 
universal function of ISGylation has not been described, it is thought to play a role in 
diverse cellular processes, including antiviral immunity (84). Less is known about IFN-α-
inducible protein 27, encoded by IFI27, but it is known to be upregulated in the PBMCs 
of SLE patients and may promote apoptosis (85; 86). The gene B2M encodes β-2-
microglobulin, which is part of the MHC-I complex and is known to be upregulated with 
IFN-γ stimulation.  
IFNA1 or IFNB1, which encode an IFN-α isoform and IFN-β, respectively, were 
not detected in βLox5 cells treated with IL-1β, TNF-α, and IFN-γ (data not shown). 
Furthermore, no IFN-α was detected in cytokine-treated βLox5 cell supernatants by an 
ELISA kit designed to detect eight variations of this protein (data not shown). Thus, 
these results suggest ISG15 and IFI27 expression levels were not regulated by 
autocrine effects of IFN-α and IFN-β produced in response to stimulation with pro-
inflammatory cytokines. 
 On the other hand, regulation of ISG15 and IFI27 may have been partially 
mediated by ER stress. Several studies have demonstrated crosstalk between ER stress 
and pro-inflammatory pathways in cells. In particular, the IRE1 branch of the UPR 
signals through TNF receptor-associated factor 2 (TRAF2), which leads to activation of 
JNK and NF-κB. Furthermore IRE1 signaling initiates RIDD, which generates mRNA 
fragments that can stimulate intracellular innate immune receptors. This process, along 
with the transcription factor XBP1s, also activated by IRE1, can upregulate IRF 
transcription factors (23). Thus, the changes in interferon stimulated gene expression 
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observed with TUDCA (Figure 35), may be due to modulation of ER stress, particularly 
IRE1 signaling. 
 Interestingly, studies have shown IRE1 signaling can be activated independently 
of PERK and ATF6 (87). This activation has been shown to occur in macrophages 
following TLR2 and TLR4 stimulation and was found to be required for pro-inflammatory 
cytokine production (88). If IRE1 were activated in cytokine-treated pancreatic beta cells 
but not PERK or ATF6, differential activation could explain why TUDCA was effective in 
blocking HSP90 release, while at the same time DDIT3 and HSPA5 were not 
upregulated with 24 hours of cytokine stress in these experiments (Figure 29). 
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Figure 35. TUDCA inhibits expression levels of specific interferon-regulated genes 
in pancreatic beta cells treated with pro-inflammatory cytokines. Human βLox5 
cells were treated with media alone, 0.2 mM, or 1 mM TUDCA for 6 hours at 37°C prior 
to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. Following incubation, cells were 
harvested for RNA isolation and cDNA synthesis. Expression levels of ISG15 (A), IFI27 
(B), and B2M (C) were analyzed by qRT-PCR (UD, undetected). Data are mean + SEM 
of N=3 experiments. *p < 0.05, **p < 0.01, ****p < 0.0001 Two-way ANOVA with Tukey’s 
correction for multiple comparisons.  
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Figure 36. Expression levels of interferon-regulated genes in primary cadaveric 
islet cells treated with pro-inflammatory cytokines. Primary human cadaveric islets 
were also treated for 24 hours with IL-1β, TNF-α, and IFN-γ at 37°C. Following 
incubation, cells were harvested for RNA isolation and cDNA synthesis. Expression 
levels of ISG15 (A), IFI27 (B), and B2M (C) were analyzed by qRT-PCR. Data are actual 
values of N=3-4 islet donors. **p < 0.01 Two-tailed, ratio paired t test. 
C. Beta Cell Cytokine Stress and IRE1 Endonuclease Activity 
To determine whether IRE1 signaling was responsible for cytokine-induced 
HSP90 release in pancreatic beta cells, βLox5 cells were pre-treated with a 
pharmacological inhibitor of IRE1 endonuclease activity, 4μ8C, for 6 hours at 37°C prior 
to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. We hypothesized that IRE1 
inhibition would inhibit HSP90 release in response to cytokine stress in these cells. 
However, contrary to our hypothesis, βLox5 cells pre-treated with 4μ8c released 
significantly more HSP90 in response to cytokine stress as measured by ELISA (Figure 
37 A). This increase in HSP90 release was not found to be the result of increased cell 
permeability, as LDH assays demonstrated improved viability with 4μ8c treatment 
(Figure 37 B). Thus, IRE1 signaling would appear to limit HSP90 release in response to 
cytokine stress.  
However, 4μ8c specifically inhibits the endonuclease activity of IRE1, which is 
responsible for XBP1 splicing and RIDD. As mentioned previously, IRE1 also exhibits a 
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less well understood kinase activity that is thought to be important for JNK activation 
(24). Thus, IRE1 kinase activity and subsequent JNK activation may be important for 
HSP90 release in pancreatic beta cells in response to cytokine stress. Inhibiting IRE1 
endonuclease activity with 4μ8c may have caused an increase in IRE1-mediated JNK 
activation, thus increasing HSP90 release in response to cytokine stress. 
 
Figure 37. Pharmacological inhibition of IRE1 endonuclease activity increases 
HSP90 release and viability in response to cytokine stress in pancreatic beta cells. 
Human βLox5 cells were treated with media alone, 10 μM, or 50 μM 4μ8c for 6 hours at 
37°C prior to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. After incubation, media 
was harvested for HSP90 ELISA (A) and LDH assay (B). Data are mean + SEM of N=4 
experiments. HSP90 ELISA data are presented as relative to control cells without 4μ8c. 
Actual values of HSP90 were detected between 3.2-43.0 ng/mL. LDH assay data are 
presented as percent viability relative to control cells without 4μ8c. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001 Two-way ANOVA with Tukey’s correction for multiple 
comparisons. 
D. Beta Cell Cytokine Stress and JNK Activity 
Recent studies in human beta cells have shown cytokine-induced apoptosis is 
mediated by JNK activation downstream of IRE1, rather than NO production, as has 
been shown to occur in rat beta cells. This cytokine-induced JNK activation could be 
mitigated by pre-treatment with TUDCA (28). Thus, levels of JNK phosphorylation were 
examined in pancreatic beta cells in response to cytokine stress following pre-treatment 
with TUDCA. Human βLox5 cells were treated for 6 hours with 1 mM TUDCA prior to 
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To confirm that JNK activation was playing a role in HSP90 release from 
pancreatic beta cells in response to cytokine stress, βLox5 cells were treated with a JNK 
inhibitor prior to cytokine stimulation. Human βLox5 cells were treated for 6 hours at 
37°C with the JNK inhibitor SP600125 prior to 24 hour stimulation with IL-1β, TNF-α, and 
IFN-γ. This inhibitor partially blocked HSP90 release in response to cytokine stress, 
suggesting that JNK activation is, at least in part, important for HSP90 release in 
pancreatic beta cells in response to cytokine stress (Figure 39 A). JNK inhibition also 
slightly improved viability in cytokine-treated pancreatic beta cells as measured by LDH 
assay, suggesting that inhibiting JNK activity may protect beta cells from cytokine-
induced cell death (Figure 39 B). We also confirmed the concentrations of SP600125 
used in these experiments were effective by performing IL-6 ELISAs. Indeed, IL-6 
release in response to cytokine stress was significantly inhibited by pre-treatment with 
SP600125 (Figure 39 C). 
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Figure 39. Pharmacological inhibition of JNK partially inhibits HSP90 release from 
pancreatic beta cells in response to cytokine stress. Human βLox5 cells were 
treated with media alone or 10 μM of the JNK inhibitor SP600125 for 6 hours at 37°C 
prior to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. Following incubation, media 
was harvested for HSP90 ELISA (A), LDH assay (B), and IL-6 ELISA (C). HSP90 ELISA 
data are presented as relative to control cells without SP600125. Actual values of 
HSP90 were detected between 6.8-77.1 ng/mL. LDH data are presented as percent 
viability relative to control cells without SP600125. Data are mean + SEM of N=3-4 
experiments. *p < 0.05, ***p < 0.001, ****p < 0.0001 Two-way ANOVA with Tukey’s 
correction for multiple comparisons. 
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E. Beta Cell Cytokine Stress and p38 Activity 
Although JNK inhibition was shown to be important for HSP90 release in 
pancreatic beta cells in response to cytokine stress, whether or not this JNK activation 
occurred downstream of IRE1 remained unclear. As mentioned previously, JNK is also 
activated by MAPK signaling pathways that are initiated downstream of pro-inflammatory 
cytokine receptor stimulation. Thus, to determine whether MAPK signaling was important 
for HSP90 release in response to cytokine stress, pancreatic beta cells were treated with 
a p38 inhibitor. Like JNK, p38 is a signal transducer in MAPK signaling pathways that 
are activated in response to pro-inflammatory cytokine stimulation.  
 Human βLox5 cells were treated with the p38 inhibitor SB202190 for 6 hours at 
37°C prior to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. Following incubation, 
media was harvested for HSP90 ELISA and LDH assay. Rather than inhibit HSP90 
release, pre-treatment with the p38 inhibitor SB202190 actually increased HSP90 
release in response to cytokine stress (Figure 40 A), similarly to pre-treatment with 
4μ8c. This increase in HSP90 release was found not to be due to an increase in cell 
permeability, because p38 inhibition had no effect on cell viability, as measured by LDH 
assay (Figure 40 B). Inhibition of p38 may have resulted in increased signaling through 
JNK, thus promoting increased HSP90 release. Nevertheless, HSP90 release does not 
seem to result from synergistic MAPK signaling downstream of cytokine receptor 
activation. Rather, HSP90 release in response to cytokine stress appears to be specific 
to JNK activation.  
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Figure 40. Pharmacological inhibition of p38 increases HSP90 release in 
pancreatic beta cells in response to cytokine stress without affecting viability. 
Human βLox5 cells were pre-treated with media alone, 5 μM, or 10 μM of the p38 MAPK 
inhibitor SB202190 for 6 hours at 37°C prior to 24 hour stimulation with IL-1β, TNF-α, 
and IFN-γ. Following incubation, media was harvested for HSP90 ELISA (A) and LDH 
assay (B). ELISA data are presented as relative to control cells without SB202190. 
Actual values of HSP90 were detected between 2.8-34.1 ng/mL. LDH assay data are 
presented as percent viability relative to control cells treated without SB202190. Data 
are mean + SEM of N=4 experiments. *p < 0.05, **p < 0.01 Two-way ANOVA with 
Tukey’s correction for multiple comparisons. 
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F. Confirming a Role for JNK in HSP90 Release 
To further confirm that beta cell release of HSP90 was mediated by JNK activity, 
siRNA-mediated knockdown of JNK was performed in βLox5 cells. Human βLox5 cells 
were transfected with a control or JNK-specific siRNA for 72 hours at 37°C using 
Lipofectamine 2000. Following 72 hours of transfection, JNK protein expression was 
assessed by immunoblotting, and a 25 percent decrease in JNK protein expression was 
observed in cells transfected with JNK siRNA relative to cells transfected with control 
siRNA (Figure 42 A-B). After 72 hours of transfection, cells were treated with media 
alone or IL-1β, TNF-α, and IFN-γ for an additional 24 hours at 37°C. Following 
incubation, media was harvested, and HSP90 levels were assayed by ELISA. HSP90 
release in response to cytokine stress was markedly reduced in cells transfected with 
JNK siRNA relative to cells transfected with control siRNA (Figure 42 C). These results 
further support a role for JNK activity in promoting HSP90 release from pancreatic beta 
cells in response to cytokine stress. 
Given that the relative increase in exosomal HSP90 was much greater than the 
increase in soluble HSP90 observed with cytokine stress (Figure 9), another potential 
future experiment would be to look at exosome HSP90 levels released from beta cells 
treated with SP600125 or JNK siRNA in response to pro-inflammatory cytokine stress. 
This experiment would determine whether or not exosome-associated HSP90 is 
released by a similar mechanism as soluble HSP90. 
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If HSP90 was released in response to JNK activation downstream of IRE1 
signaling, the reason why thapsigargin-treated human beta cells did not release HSP90 
(Figure 7) remained unclear, given that this chemical inducer of ER stress should 
activate the IRE1 pathway. Results of XBP1s qRT-PCR in thapsigargin-treated cells 
(Figure 29 A) suggest that indeed this pathway was induced by thapsigargin. Thus, 
levels of JNK phosphorylation were examined in thapsigargin-treated βLox5 cells by 
immunoblotting. Levels of phospho-JNK were not increased in beta cells treated with 
thapsigargin for 24 hours compared to cells treated with media alone (Figure 43). This 
result differs from that observed with pro-inflammatory cytokine treatment, which 
resulted in increased levels of JNK phosphorylation (Figure 43). These results may 
suggest the ER stress response induced by thapsigargin is different from the ER stress 
response induced by pro-inflammatory cytokines in pancreatic beta cells. This 
conclusion is supported by qRT-PCR analysis of ER stress markers in response to these 
two treatments (Figure 29). Thus, these results also offer an explanation as to why 
thapsigargin-treated beta cells did not release HSP90.  
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stress may be related to JNK activation downstream of IRE1. Pharmacological inhibition 
of IRE1 endonuclease activity did not prevent HSP90 release in response to cytokine 
stress (Figure 37); however, JNK activation is known to result from IRE1 kinase activity 
(24). Pharmacological inhibition of JNK (Figure 39), but not p38 (Figure 40), slightly 
decreased, while siRNA-mediated knockdown of JNK markedly decreased HSP90 
release in response to cytokine stress (Figure 42). Thapsigargin likely did not induce 
HSP90 release (Figure 7) as treatment with this compound did not result in beta cell 
JNK phosphorylation (Figure 43).  
Thus, the results presented here suggest JNK activation promotes HSP90 
release from pancreatic beta cells in response to cytokine stress; however, further 
studies are needed to confirm whether or not this same mechanism contributes to 
HSP90 release in response to PIC stimulation. Furthermore, these experiments provide 
in vitro evidence that beta cell stress during latent TIDM may also promote HSP90 
release in vivo, further suggesting this protein could serve as a biomarker of beta cell 
stress associated with pre-clinical TIDM. 
IV. Pharmacological Inhibition of HSP90 during TIDM in Vivo 
 Although HSP90 was found to be released from pancreatic beta cells in response 
to inflammatory stimuli known to be present during the latent period of TIDM, the in vivo 
role of HSP90 during the development of TIDM is unknown. Thus, the next objective of 
this work was to determine whether or not HSP90 inhibition could affect the development 
of TIDM in vivo.  
 The NOD mouse model, perhaps the most extensively studied model of TIDM, 
was utilized for these experiments. The spontaneous development of TIDM in these 
mice is very similar to that which occurs in humans. For example, NOD mice express 
diabetogenic MHC-II alleles as well as several non-MHC genetic risk loci. They also 
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develop insulitis, antibodies that target islet cell autoantigens, and ultimately an 
autoimmune diabetes mediated by autoreactive CD8+ T cells (45). 
 HSP90 inhibition, particularly inhibition with 17-DMAG, has shown protective 
effects in a number of autoimmune disease models, including SLE, by modulating 
immune responses (36; 37; 41). Thus, we hypothesized that HSP90 inhibition with 17-
DMAG may inhibit the development of TIDM in vivo. 17-DMAG, a semisynthetic 
derivative of the naturally occurring anti-tumor antibiotic geldanamycin, inhibits HSP90 
chaperone function by binding the ADP/ATP binding pocket, thus inhibiting client protein 
maturation and folding. These immature, unfolded client proteins are ultimately 
ubiquitinated and targeted for degradation by the proteasome (89; 90). 
 In these studies, female NOD mice were injected with PBS or 17-DMAG (2 
mg/kg) for 18 weeks, beginning at six weeks of age. This dosage was found to reduce 
inflammatory responses in a mouse model of atherosclerosis (61). Only female NOD 
mice were used in this study as female mice have a much greater rate of diabetes 
incidence (80-90%) than males (10-40%). Of note, this gender bias is not observed in 
humans (45). 
 The development of TIDM was monitored over the course of the study by 
measuring body weight and blood glucose levels once per week. Serum was collected 
once per week from a cohort of mice to monitor HSP90 levels by ELISA. A large cohort 
of moribund mice were sacrificed around 19 weeks of age and used for histology. Finally 
at 21 and 24 weeks of age, cohorts of the surviving mice were sacrificed for qRT-PCR 
analysis of islet gene expression (Figure 44). 
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To determine whether 17-DMAG treatment was effective at inhibiting HSP90 
chaperone function, expression levels of the gene Hspa1b were measured by qRT-PCR 
using cDNA samples prepared from the islet cells of NOD mice. The gene Hspa1b 
encodes another cytoplasmic chaperone, HSP70. When active, cytosolic HSP90 inhibits 
the transcription factor HSF1, which is required for the transcription of Hspa1b. Thus, if 
HSP90 is inhibited, expression of Hspa1b will increase due to increased HSF1 activity 
(37). 
 At age 21 weeks, several 17-DMAG-treated mice exhibited increased expression 
of Hspa1b, although overall, the increase observed in the 17-DMAG-treated group was 
not statistically significant from the PBS-treated group (Figure 45 A). However, in the 
cohort of mice sacrificed at age 24 weeks, all mice showed an increase in Hspa1b 
expression, and the increase overall observed in the 17-DMAG-treated group was 
statistically significant compared to the PBS group (Figure 45 B). No differences in 
Hspa1b expression were observed in non-diabetic (ND) mice versus mice with TIDM for 
PBS or 17-DMAG-treated groups (Figure 45 C-D). Thus overall, 17-DMAG did appear to 
effectively inhibit HSP90 function in vivo, although perhaps not in some mice from the 
cohort sacrificed at 21 weeks. 
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Figure 45. Expression levels of Hspa1b in islet cells from NOD mice treated with 
17-DMAG. Female NOD mice were treated with PBS and 17-DMAG as described in 
Figure 44. Whole pancreatic islets were harvested from mice sacrificed at age 21 (A and 
C) and 24 weeks (B and D) for RNA isolation and cDNA synthesis. Expression levels of 
Hspa1b were measured by qRT-PCR. Data presented in the bottom two panels are the 
same PBS and 17-DMAG data presented in the top panels, but relative expression 
values from non-diabetic (ND) mice and mice with TIDM have been distinguished. Data 
in A and B were analyzed by two-tailed, unpaired t test. Data in C and D were analyzed 
by two-way ANOVA with Tukey’s correction for multiple comparisons. *p < 0.05, **p < 
0.01. 
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 Serum was collected once per week from a cohort of mice during the course of 
the study, and HSP90 levels were measured by ELISA. Although elevated levels of 
HSP90 were detected as the mice approached fifteen weeks of age, no differences were 
observed in serum HSP90 levels between the 17-DMAG and PBS-treated groups 
(Figure 46). These results suggest that inhibition of HSP90 chaperone function with 17-
DMAG did not affect the release of cytoplasmic HSP90 from cells into the serum. 
 
Figure 46. Serum levels of HSP90 in NOD mice treated with 17-DMAG. Female NOD 
mice were treated with PBS or 17-DMAG as described in Figure 44. Serum was 
collected once per week from a cohort of mice, and HSP90 levels were measured by 
ELISA. Data are mean ± SEM of N=4 mice per group. 
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 As mentioned previously, pharmacological inhibition of HSP90 has been shown 
to limit the development of autoimmune diseases by attenuating inflammatory responses 
(36-41). Treatment with 17-DMAG was also found to inhibit inflammatory responses in a 
model of atherosclerosis (61). Thus, we hypothesized that HSP90 inhibition would 
attenuate inflammatory responses in NOD mice.  
 Islet gene expression levels of three inflammatory genes, Nos2, Il6, and Hmgb1 
were measured by qRT-PCR. No difference in Nos2 expression was observed between 
PBS and 17-DMAG-treated mice at 21 weeks of age (Figure 47 A); however, at 24 
weeks of age, a trend toward decreased expression of Nos2 was observed in 17-DMAG 
treated mice (Figure 47 B). These variations may reflect an absence of infiltrating 
immune cells at this time point, possibly because the beta cells have already been 
largely destroyed. No differences in Il6 expression were observed in either cohort of 
mice (Figure 47 E-H). Expression levels of Hmgb1, which encodes another 
inflammatory mediator, were slightly upregulated with 17-DMAG treatment at both time 
points (Figure 47 I-J). 
 By histology, insulitis scores were slightly worse in 17-DMAG-treated diabetic 
mice than in PBS-treated diabetic mice sacrificed at 19-20 weeks of age (Figure 48). 
Taken together, these results suggest that, contrary to our hypothesis, HSP90 inhibition 
with 17-DMAG did not dampen inflammatory responses in the NOD mouse model of 
TIDM, but rather may have exacerbated inflammation. To confirm this result, we plan on 
looking at transcription of other inflammation and immune cell markers by qRT-PCR. 
114 
 
Figure 47. Expression levels of Nos2, Il6, and Hmgb1 in islet cells from NOD mice 
treated with 17-DMAG. Female NOD mice were treated with PBS or 17-DMAG as 
described in Figure 44. Whole pancreatic islets were harvested from mice sacrificed at 
age 21 and 24 weeks for RNA isolation and cDNA synthesis. Expression levels of Nos2 
(A-D), Il6 (E-H), and Hmgb1 (I-L) were measured by qRT-PCR. Data presented in the 
right two columns are the same PBS and 17-DMAG data presented in the left two 
columns, but relative expression values from non-diabetic (ND) mice and mice with 
TIDM have been distinguished. Mice with undetectable levels of expression were 
assigned a value of 0, and statistics were not performed (Nos2 and Il6). Data in the left 
two columns were analyzed by two-tailed, unpaired t test, while data in the right two 
columns were analyzed by two-way ANOVA with Tukey’s correction for multiple 
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 (Hmgb1).  
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 In addition to insulitis and markers of inflammatory stress, other parameters of 
TIDM were examined over the course of the present study. As PBS and 17-DMAG-
treated mice began to develop diabetes, 17-DMAG-treated diabetic mice began to lose 
weight at a faster rate as they approached 19 weeks of age (Figure 49). These results 
suggest that 17-DMAG-treated diabetic mice may have been getting sicker than the 
PBS-treated diabetic mice, perhaps due to an increase in some form of metabolic stress 
in the context of diabetes. To confirm this conclusion, future experiments are needed in 
which control and NOD mice are each treated with 17-DMAG. Nevertheless, these data 
are also consistent with the increased insulitis scores that were observed in the 17-
DMAG-treated diabetic mice. 
 Consistent with the data described above, gene expression levels of Ins1, which 
encodes insulin, were elevated in 17-DMAG-treated non-diabetic mice relative to PBS-
treated non-diabetic mice (Figure 50). Both PBS and 17-DMAG-treated diabetic mice 
expressed very low levels of Ins1 (Figure 50), as the beta cell mass in these mice was 
likely over 90 percent depleted (18). These results suggest that beta cells in 17-DMAG-
treated mice may actually have been experiencing a greater degree of stress than beta 
cells from PBS-treated mice, as the demand for insulin release from the beta cells of the 
17-DMAG-treated mice appeared to be higher. 
 On the other hand, these results may suggest that 17-DMAG treatment promoted 
the development of insulin resistance in these mice, as insulin resistance is known to be 
closely related to hyperinsulinemia (91). Several anti-cancer therapies such as 
glucocorticoids, chemotherapy, hormonal therapies, and other targeted drugs can 
actually induce insulin resistance (92); however, to our knowledge, this effect has not 
been shown with HSP90 inhibitors. In fact, the HSP90 inhibitor AUY922 actually 
improved insulin sensitivity in the diet-induced obese mouse model of insulin resistance 
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(93). Nevertheless, the results presented here suggest 17-DMAG treatment may have 
increased levels of pancreatic beta cell stress.    
 
Figure 49. Average weight of NOD mice treated with 17-DMAG. Female NOD mice 
were treated with PBS or 17-DMAG as described in Figure 44. Body weights were 
measured once per week during the course of the study. ND = not diabetic. TIDM = type 
I diabetes mellitus. Data are mean ± SEM. ****p < 0.0001 One-way ANOVA.  
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Figure 50. Ins1 gene expression levels in islet cells from NOD mice treated with 
17-DMAG. Female NOD mice were treated with PBS or 17-DMAG as described in 
Figure 44. Whole pancreatic islets were harvested from mice sacrificed at age 21 (A) 
and 24 weeks (B) for RNA isolation and cDNA synthesis. Expression levels of Ins1 were 
measured by qRT-PCR. Data are mean ± SEM. *p < 0.05, **p < 0.01 Two-way ANOVA 
with Tukey’s correction for multiple comparisons.  
To further characterize the islet cell stress response in NOD mice treated with 
17-DMAG, expression levels of ER stress-associated genes were examined by qRT-
PCR. ER stress is known to precede the development of TIDM in the NOD mouse model 
(64). Expression levels of Ddit3, which encodes CHOP, were elevated in 17-DMAG-
treated mice relative to PBS-treated mice, although not significantly at 21 weeks of age 
(Figure 51 A). This increase became statistically significant at 24 weeks of age (Figure 
51 B). Expression levels of Hspa5, which encodes BiP, were elevated in 17-DMAG-
treated mice at 21 and 24 weeks of age compared to PBS-treated mice (Figure 51 E-F). 
Furthermore, expression levels of Hsp90b1, which encodes GRP94, were increased in 
17-DMAG-treated mice at 21 weeks of age (Figure 51 I), and this increase was more 
pronounced at 24 weeks of age (Figure 51 J). Overall, the diabetic mice in each 
treatment group expressed lower levels of these genes, likely because beta cells were 
mostly depleted or approaching apoptosis in these animals. 
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 Together, these results suggest that islet cells from 17-DMAG-treated mice 
experienced an exacerbated ER stress response compared to islet cells from the PBS-
treated mice. These results are consistent with those shown in Figure 50, as the non-
diabetic 17-DMAG-treated mice were making more insulin mRNA than non-diabetic 
PBS-treated mice, suggesting the insulin protein demand was higher in 17-DMAG-
treated mice. 
 In addition to cytoplasmic HSP90α and HSP90β, 17-DMAG has been shown to 
inhibit GRP94 and TRAP1 (94). Thus, 17-DMAG inhibition of the ER chaperone GRP94 
in NOD mice may have further promoted ER stress responses in islet cells of 17-DMAG-
treated mice. 
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Figure 51. Expression levels of UPR genes in islet cells from NOD mice treated 
with 17-DMAG. Female NOD mice were treated with PBS or 17-DMAG as described in 
Figure 44. Whole pancreatic islets were harvested from mice sacrificed at age 21 and 24 
weeks for RNA isolation and cDNA synthesis. Expression levels of Ddit3 (A-D), Hspa5 
(E-H), and Hsp90b1 (I-L) were measured by qRT-PCR. Data presented in the right two 
columns are the same PBS and 17-DMAG data presented in the left two columns, but 
relative expression values from non-diabetic (ND) mice and mice with TIDM have been 
distinguished. Data in the left two columns were analyzed by two-tailed, unpaired t test, 
while data in the right two columns were analyzed by two-way ANOVA with Tukey’s 
correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Because levels of Ins1 and ER stress-associated genes were elevated in 17-
DMAG-treated mice, we hypothesized that other stress-associated genes may have 
been affected by 17-DMAG treatment. Expression levels of Hsp90aa1 and Hsp90ab1, 
which encode the HSP90α and HSP90β cytosolic isoforms of HSP90, respectively, were 
examined by qRT-PCR. Results of these experiments showed that expression levels of 
both of these genes were upregulated in mice treated with 17-DMAG at 24, but not 21, 
weeks of age (Figure 52 A-B, E-F). No differences in upregulation were observed in 
non-diabetic and diabetic mice treated with 17-DMAG (Figure 52 C-D, G-H). 
 These results are somewhat surprising, given that Hsp90aa1 and Hsp90ab1 
should both be induced in response to HSF1 activation (95), which is known to occur 
with administration of 17-DMAG. These results are consistent with those presented in 
Figure 45, in which Hspa1b expression was not induced in all 17-DMAG treated mice at 
21 weeks of age. These results suggest 17-DMAG may have taken slightly longer to 
have an effect in vivo. However, these mice had been injected for a total of 15 and 18 
weeks, respectively. Alternatively, the dosage of 17-DMAG used may not have had an 
effect on a cohort of the mice sacrificed at 21 weeks. 
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Figure 52. Expression levels of Hsp90aa1 and Hsp90ab1 in islet cells from NOD 
mice treated with 17-DMAG. Female NOD mice were treated with PBS or 17-DMAG as 
described in Figure 44. Whole pancreatic islets were harvested from mice sacrificed at 
age 21 and 24 weeks for RNA isolation and cDNA synthesis. Expression levels of 
Hsp90aa1 (A-D) and Hsp90ab1 (E-H) were measured by qRT-PCR. Data presented in 
the right two columns are the same PBS and 17-DMAG data presented in the left two 
columns, but relative expression values from non-diabetic (ND) mice and mice with 
TIDM have been distinguished. Data in the left two columns were analyzed by two-tailed, 
unpaired t test, while data in the right two columns were analyzed by two-way ANOVA 
with Tukey’s correction for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. 
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 Recent studies have also shown that in addition to activating the UPR and 
promoting apoptosis, ER stress can induce macroautophagy, a stress-induced process 
in which eukaryotic cells recycle macromolecules and organelles from their own 
cytoplasm (96). Thus, expression levels of two genes involved in macroautophagy, 
Sqstm1, which encodes SQSTM1/p62, and Map1lc3a, which encodes LC3, were 
measured by qRT-PCR. At 21 and 24 weeks of age, Sqstm1 and Map1lc3a expression 
levels were both increased in 17-DMAG-treated mice compared to PBS-treated controls 
(Figure 53 A-B, E-F). However, no significant differences were observed between non-
diabetic and diabetic mice (Figure 53 C-D, G-H). Together, the results presented in 
Figures 51 and 53 are consistent with previous studies that have shown Sqstm1 and 
Map1lc3a are upregulated downstream PERK signaling and ATF4 activation (97).   
 Overall, 17-DMAG treatment did not have an effect on diabetes incidence in 
NOD mice (Figure 54 A). A similar trend was observed in the mice that survived past 19 
weeks of age that were sacrificed at 21 and 24 weeks of age for qRT-PCR (Figure 54 
B). If two 17-DMAG-treated mice from the qRT-PCR groups that had extremely low 
expression of Hspa1b, the remaining 17-DMAG-treated mice appeared to have a slightly 
lower incidence of TIDM (Figure 54 C); however, this result was still not significant. 
Thus, our overall conclusion is that HSP90 inhibition does not affect the 
incidence of TIDM in vivo. However, given that 17-DMAG-treated mice that developed 
diabetes had worse insulitis than PBS-treated diabetic mice (Figure 48), lost more 
weight than PBS-treated mice (Figure 49), and that islet cells from 17-DMAG treated 
mice express higher levels of stress-associated genes than PBS-treated mice (Figures 
50-53), HSP90 inhibition appears to exacerbate islet cell stress during the course of 
TIDM in vivo. Alternatively, the increased weight loss observed in the 17-DMAG treated 
diabetic mice may have been due to increased stress responses in other tissues such as 
muscle or adipose tissue. Nevertheless, HSP90 inhibition would likely not prevent TIDM 
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in human patients at risk for developing the disease. Rather, HSP90 inhibition may have 
adverse effects on beta cell stress, dysfunction, and death. 
 
Figure 53. Expression levels of Map1lc3a and Sqstm1 in islet cells from NOD mice 
treated with 17-DMAG. Female NOD mice were treated with PBS or 17-DMAG as 
described in Figure 44. Whole pancreatic islets were harvested from mice sacrificed at 
age 21 and 24 weeks for RNA isolation and cDNA synthesis. Expression levels of 
Map1lc3a (A-D) and Sqstm1 (E-H) were measured by qRT-PCR. Data presented in the 
right two columns are the same PBS and 17-DMAG data presented in the left two 
columns, but relative expression values from non-diabetic (ND) mice and mice with 
TIDM have been distinguished. Data in the left two columns were analyzed by two-tailed, 
unpaired t test, while data in the right two columns were analyzed by two-way ANOVA 
with Tukey’s correction for multiple comparisons. *p < 0.05, ***p < 0.001. 
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Figure 54. Diabetes incidence in NOD mice treated with 17-DMAG. Female NOD 
mice were treated with PBS or 17-DMAG as described in Figure 44. Blood glucose 
levels were measured once per week. Mice were considered diabetic after two 
consecutive blood glucose readings above 300 mg/dl. Data in panel A are for all mice 
(PBS N=34, 17-DMAG N=33), while data in panel B are the surviving mice sacrificed for 
qRT-PCR at 21 and 24 weeks of age (PBS N=17, 17-DMAG N=17). Data in panel C are 
the same mice as in B, but two mice that had extremely low expression level values of 
Hspa1b were excluded (PBS N=17, 17-DMAG N=15). Data were analyzed by Mantel-
Cox test.  
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DISCUSSION 
I. Rationale 
 Currently, a major obstacle on the road to TIDM prevention is a lack of known 
biological markers that could identify patients in the pre-clinical, latent phase of TIDM 
development. Recent collaborative studies from our lab and others have shown serum 
levels of the alpha cytoplasmic isoform of HSP90 are elevated in newly diagnosed TIDM 
patients relative to control subjects (31). Furthermore, other studies have shown patients 
with TIDM have elevated levels of circulating class-switched IgG1 and IgG3 
autoantibodies to HSP90 compared to control subjects. These antibody isotypes are 
produced during Th1-mediated immune responses, which predominate the autoimmune 
response in TIDM (35). Together, these results suggest HSP90 may be released 
extracellularly during the development of TIDM. Thus, HSP90 may be able to serve as a 
predictive biomarker of beta cell stress and latent TIDM. If true, serum HSP90 levels 
could be measured in the clinic to identify patients at risk for progressing to TIDM, and 
treatments aimed at disease prevention could be more appropriately implemented. 
II. Release of HSP90 from Pancreatic Beta Cells  
In light of this information, we hypothesized HSP90 may be released from 
pancreatic beta cells during periods of beta cell stress associated with latent TIDM. 
HSP90 has previously been shown to be released from cells in response a number of 
different stress events, including heat shock, oxidative stress, and hypoxia (54). 
Studies here using the human pancreatic beta cell lines βLox5 and 1.1B4 demonstrated 
that HSP90 was released in response to stimulation with a combination of pro-
inflammatory cytokines that included IL-1β, TNF-α, and IFN-γ, but not in response to 
stimulation with thapsigargin or high glucose treatment (Figure 7 A-B).  
The results obtained with these human beta cell lines differed from those 
obtained with the murine insulinoma cell line MIN6, which released HSP90 in response 
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to all three stimuli, although the most robust release was observed with pro-inflammatory 
cytokines (Figure 7 C). These incongruities may be due to interspecies differences 
between human and mouse. To support this conclusion, a recent study has shown that 
cytokines induce ER stress in mouse, rat, and human beta cells via different 
mechanisms (28), suggesting beta cells from different species may respond differently to 
various stress treatments. Alternatively, MIN6 cells may be more sensitive to 
thapsigargin and high-glucose treatment, as this insulinoma cell line is likely producing 
high levels of insulin relative to the human beta cell lines and may therefore reach ER 
processing capacity more quickly with additional stress. For these reasons, the majority 
of experiments in this work were performed with human cell lines. 
Next, we confirmed that primary human cadaveric islet cells also release HSP90 
in response to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ (Figure 7 D). Human 
βLox5 cells were used as a model in the majority of experiments in this work because 
they responded to cytokine stimulation most similarly to human islets in terms of gene 
expression of HSP90 isoforms (Figures 11, 13-16), oxidative stress markers (Figures 
20, 23-24), ER stress markers (Figures 29-30), and interferon-stimulated genes 
(Figures 35-36). The 1.1B4 cell line may have responded differently (Figures 20 and 
24) due to the fact that this cell line was derived by electrofusion of adult cadaveric islet 
cells with the immortalized PANC-1 epithelial cell line (60). Thus, this cell line may 
exhibit characteristics of epithelial cells as well as beta cells. Additionally, electrofusion 
can generate aneuploidy in cells, which could also potentially affect gene expression.  
Interestingly in addition to pro-inflammatory cytokines, βLox5 cells also released 
HSP90 in response to 24 hour stimulation with an agonist for TLR3 but not TLR4 
(Figure 18 C-D), even though these cells expressed both receptors (Figure 17 A). Thus, 
HSP90 appeared to be released in response to distinct inflammatory stimuli. 
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III. Mechanism of HSP90 Release 
 We next wanted to understand the mechanism by which HSP90 was released 
from beta cells. The combination of pro-inflammatory cytokines used in these 
experiments has been shown to be cytotoxic to primary islet cells (63). Thus, HSP90 
may have been released non-specifically from cells as a result of compromised cell 
membrane integrity associated with cell death (Figure 55 A). Indeed, others have shown 
HSP90 and other DAMPs are released by necrotic, but not apoptotic, cells (48). Results 
here showed a decrease in viability by LDH assay of approximately two to five percent in 
human βLox5 cells treated with IL-1β, TNF-α, and IFN-γ for 24 hours relative to control-
treated cells. However, significant decreases in viability were not observed until 48 hours 
post-treatment (Figure 8 E). These results are consistent with other studies showing 
increased beta cell death in response to stimulation with cytokines for 48 hours (28; 98). 
Thus, HSP90 does not appear to be passively released as a result of cell death after 24 
hours of cytokine treatment. However, HSP90 may be passively leaking from cells in 
response to cytokine stress at later time points associated with significant levels of cell 
death. 
One limitation associated with the LDH assay is cell confluency. A more 
confluent monolayer of cells will naturally exhibit higher LDH activity than a less 
confluent monolayer. Thus, if any stress treatment or pharmacological agent utilized in 
these experiments were to affect cell growth or confluency, the LDH assay results could 
be skewed accordingly. To confirm the results obtained here with LDH assays, beta cell 
apoptosis and necrosis could be examined via microscopy (28). 
Nevertheless, to further support the conclusion that cytokine stress does not 
result in non-specific release of HSP90 at 24 hours, no extracellular HSC70 or HSP70 
was detected by ELISA following 24 hours of stimulation with IL-1β, TNF-α, and IFN-γ 
(data not shown). These results suggest cytosolic proteins were not passively leaking 
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out of cells in response to stimulation with pro-inflammatory cytokines. Moreover, 
changes in HSP90 release were not always consistent with changes in LDH activity. For 
example, pre-treatment with TUDCA inhibited HSP90 release in response to stimulation 
with pro-inflammatory cytokines and PIC (Figure 32 A-B); however, pre-treatment with 
TUDCA did not affect viability in response to 24 hour cytokine stimulation (Figure 32 C), 
while it slightly improved viability in response to TLR3 stimulation (Figure 32 D). These 
results suggest a portion of the HSP90 released in response to 24 hour stimulation with 
PIC, but not pro-inflammatory cytokines, may have resulted from or been associated 
with cell death. However, this result does not definitively prove that HSP90 was 
passively leaking from cells as a result of cell death. Furthermore, pre-treatment with the 
IRE1 endonuclease inhibitor 4μ8C increased levels of HSP90 release in response to 
cytokine stress, while simultaneously increasing viability by LDH assay (Figure 37 A-B).  
Other studies have shown HSP90 can be released from cells in the context of 
exosomes (51; 68). Results here suggest that while some extracellular HSP90 was 
associated with exosomes, the majority of HSP90 released in response to 24 hour 
cytokine stimulation was soluble (Figure 9) (Figure 55 B). Thus, results here 
demonstrate that in response to 24 hour stimulation with pro-inflammatory cytokines, the 
majority of HSP90 is released specifically by an as of yet unknown secretory mechanism 
(Figure 55 C). Together, these results are consistent with previous studies suggesting 
HSP90 can be actively released from cells in response to stress (53; 55; 58). Secretion 
of HSP90 has been demonstrated in a number of studies: however, the underlying 
secretory mechanism remains elusive (56; 57). 
  
F
h
IF
in
af
ex
re
 
 
igure 55. Po
ere have de
N-γ, HSP90
tegrity asso
ter longer p
tracellular H
leased by a
tential ave
monstrated 
 is likely no
ciated with c
eriods of tim
SP90 is as
n unknown 
nues of HS
that in respo
t passively r
ell death (A
e associate
sociated ex
secretory m
 
130 
P90 release
nse to 24 h
eleased as 
). This mec
d with signif
osomes (B)
echanism (C
 from panc
our stimulat
a result of im
hanism likel
icant levels
; however, t
).  
reatic beta
ion with IL-1
paired cell
y becomes 
 of cell deat
he majority o
 cells. Stud
β, TNF-α, a
 membrane 
more releva
h. A portion 
f HSP90 is
 
ies 
nd 
nt 
of 
 
131 
A recent study using the breast cancer cell line MCF-7 showed that secreted 
HSP90α is a truncated form of the protein in which the C-terminal EEVD motif has been 
removed and in which residue Thr-90 has been phosphorylated (57); however, the 
authors did not identify the protease required for cleavage of the EEVD motif. Future 
studies are needed to determine whether or not secretion of HSP90 from beta cells in 
response to pro-inflammatory cytokine stimulation is regulated by similar post-
translational modifications of HSP90.  
Another recent study has demonstrated that various proteins involved in 
inflammation, cytoprotection, and tissue repair are secreted by an unconventional, rather 
than ER/Golgi-dependent, secretion mechanism that requires cleavage by caspase-1 
(99), and HSP70 has been shown to be secreted by a similar mechanism (100). HSP90 
does not contain a classical N-terminal secretion signal peptide, and therefore may also 
be secreted by such an unconventional mechanism (57). More work is needed to 
understand the specific secretory mechanism by which HSP90 is secreted.  
IV. HSP90 Release and Oxidative Stress 
 We next sought to understand the intracellular signaling events that promoted 
HSP90 release from human pancreatic beta cells in response to stimulation with pro-
inflammatory cytokines and PIC. Because HSP90 was not released in response to 
treatment with thapsigargin, a SERCA inhibitor that induces ER stress, we hypothesized 
that ER stress did not contribute to HSP90 release, even though pro-inflammatory 
cytokines and PIC have both been shown previously to induce ER stress in pancreatic 
beta cells (28; 66; 79). 
 In pancreatic beta cells, pro-inflammatory cytokine stimulation induced 
expression of NOS2, which encodes the NO-producing enzyme iNOS (Figure 20); 
therefore, we hypothesized oxidative stress mediated by NO may play a role in HSP90 
release. Oxidative stress is caused by the accumulation of RNS and ROS within cells. 
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RNS and ROS contain unpaired electrons and are therefore highly reactive molecules 
that can cause significant damage to various cellular structures (29). In pancreatic islet 
cells, NO has been shown to induce detrimental effects on islet function and viability by 
damaging mitochondria and mitochondrial proteins (101). Interestingly, a recent study 
showed that nitration of HSP90 in response to oxidative stress could induce cell death in 
motor neurons (102). Thus, we hypothesized that NO production in pancreatic beta cells 
may promote oxidative stress and HSP90 release. However, pre-treatment of βLox5 
cells with the iNOS inhibitor 1400W did not affect HSP90 release in response to pro-
inflammatory cytokine stimulation (Figure 21).  
Expression levels of NOS2 were low in both βLox5 and primary islet cells 
(approximate CT = 32) (Figure 20). Consistent with these results, others have reported 
βLox5 cells do not produce NO in response to cytokine stimulation (98), and similar 
results were shown with the human beta cell line EndoC-βH1 (103). Furthermore, 
studies from two independent groups have shown NO production is dispensable for 
cytokine-mediated apoptosis in EndoC-βH1 cells (28; 103). Thus, primary human 
pancreatic beta cells may not produce a significant amount of NO. However, primary 
human pancreatic islet cells are known to produce NO in response to stimulation with 
pro-inflammatory cytokines, and this NO is a major mediator of cytokine-induced 
damage of human islet cells (101; 103). Given the presence of multiple cell types within 
islets, the NO detected in these studies may have arisen from another endocrine cell 
type such as alpha cells. More research is therefore needed to determine whether or not 
primary human beta cells produce NO and whether or not it is cytotoxic to these cells. 
This work will hopefully be possible in the future with the development of reagents to sort 
human beta cells from mixed islet cell populations by flow cytometry. In the meantime, 
determining whether or not pre-treatment with 1400W could inhibit HSP90 release in 
response to cytokine stress in primary human islet cells may be worthwhile. 
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 Another oxidative stress factor that was induced in human beta cells in response 
to cytokine stress was HIF1A (Figure 23). Expression of HIF1A can be induced by the 
transcription factor NF-κB (77), which is activated in response to pro-inflammatory 
cytokine stimulation (Figure 1). In the presence of ROS, HIF-1α can be stabilized and 
transcriptionally active, even under normoxic conditions (Figure 22). Here cytokine 
stress increased the expression of HIF-1α target genes in beta cells (Figure 24), 
suggesting HIF-1α transcriptional activity increased with cytokine treatment in the 
present study. Interestingly, human fibroblast cells have been shown to secrete HSP90 
in response to hypoxia and HIF-1α activation (55). Thus, we hypothesized that increased 
HIF-1α activity in beta cells may promote HSP90 release. However, pharmacological 
inhibition of HIF-1α with chetomin did not inhibit HSP90 release in response to cytokine 
stress (Figure 25). Moreover, pharmacological stabilization of HIF-1α with DMOG did 
not promote HSP90 release from beta cells (Figure 27). These results suggest that, 
unlike in fibroblasts, HIF-1α activity in beta cells does not promote HSP90 release. 
 At this point, HSP90 release did not appear to be regulated by cytokine-induced 
oxidative stress mediated through iNOS or HIF-1α. To determine once and for all 
whether any source of oxidative stress could promote HSP90 release in response to pro-
inflammatory cytokine stimulation, βLox5 cells were pre-treated with the antioxidant NAC 
for 6 hours prior to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. Surprisingly, 1 mM 
NAC actually increased levels of HSP90 release in both control- and cytokine-treated 
cells (Figure 28). These unexpected results suggest that a more reducing environment 
in the cell may promote HSP90 release. 
Protein folding in the ER requires oxidizing conditions for the formation of 
intramolecular and intermolecular disulfide bonds (29). Therefore, NAC treatment may 
have placed additional stress on protein folding in cells, and this stress may have 
resulted in increased HSP90 release. More work is needed to understand how pro-
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inflammatory cytokine stimulation affects the redox environment in beta cells and what 
role the redox environment plays in beta cell stress responses and HSP90 release. 
V. Pro-Inflammatory Cytokine Stimulation and Subsequent Activation of a Non-
Canonical UPR in Pancreatic Beta Cells 
 In light of the results discussed above, we next decided to revisit the possibility 
that HSP90 release from pancreatic beta cells may be related to cytokine-induced ER 
stress. In response to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ, βLox5 
expression levels of the ER stress-associated markers HSP90B1 (GRP94) and XBP1s 
were slightly increased relative to control cells, while ATF3 expression increased 
approximately ten-fold; however, these increases were not as significant as the robust 
responses induced by thapsigargin treatment (Figure 14, 29). Similar results were 
observed with primary human islet cells (Figure 16, 30), although the results obtained 
with these cells were more variable and may reflect genetic differences among the 
individual donors. Overall these results suggest pancreatic beta cells may require a 
longer incubation with pro-inflammatory cytokines in order to fully induce the UPR. 
Others have shown significant increases in EndoC-βH1 expression levels of XBP1s, 
DDIT3 (CHOP), and HSPA5 (BiP) after 48 hours of treatment with IL-1β, TNF-α, and 
IFN-γ; however, these increases were all less than five-fold relative to control-treated 
cells (28). 
Another possibility is that stimulation with IL-1β, TNF-α, and IFN-γ may induce a 
non-canonical form of the UPR in pancreatic beta cells. Classically, the UPR is thought 
of as a response to ER stress that increases the protein-folding capacity of the ER by 
upregulating expression of ER chaperones, such as GRP94 and BiP, while 
simultaneously blocking translation of proteins not involved in alleviating ER stress. 
However, this view is quickly becoming outdated, as more and more studies are 
identifying new roles for the UPR in regulating a variety cellular processes, including 
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metabolism, inflammation, and apoptosis (104). One such “non-canonical” UPR pathway 
is the activation of JNK through phosphorylation mediated by the UPR sensor IRE1 
(Figure 56) (104). 
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Once activated, IRE1 binds TRAF2, an adaptor protein that facilitates JNK 
activation through apoptosis signal-regulating kinase 1 (ASK1). In the context of the 
UPR, JNK activation has been shown to initiate inflammatory responses via AP-1 
activation as well as promote survival by initiating autophagy. On the other hand, JNK 
activation downstream of IRE1 has also been shown to promote apoptosis in cells with 
unsurmountable levels of ER stress (Figure 56) (23; 24). Interestingly, a recent study 
showed that pro-inflammatory cytokine-mediated apoptosis of EndoC-βH1 cells was 
facilitated, at least in part, by activation of JNK. In this study, the authors also showed 
that siRNA-mediated knockdown of IRE1 reduced JNK phosphorylation in response to 
cytokine stress, suggesting that JNK was activated downstream of IRE1. In this same 
study, the authors showed that pre-treating EndoC-βH1 cells with the chemical 
chaperone TUDCA resulted in decreased levels of JNK phosphorylation and protection 
from cytokine-mediated apoptosis (28). 
TUDCA, a bile acid that functions as a chemical chaperone and restores 
homeostasis during periods of ER stress, has been shown to prevent beta cell death and 
inhibit the development of TIDM in two mouse models of disease (82). In the present 
study, pre-treatment with TUDCA inhibited beta cell HSP90 release in response to 
cytokine stress (Figure 32). Therefore, these results suggest ER stress likely plays 
some role in HSP90 release from pancreatic beta cells in response to pro-inflammatory 
cytokine stimulation.  
We next sought to determine whether or not TUDCA could inhibit JNK 
phosphorylation in response to cytokine stress, as was observed in the study by Brozzi, 
et al (28). We chose to look at JNK phosphorylation at two time points: 30 minutes and 
24 hours following the addition of cytokines. We hypothesized that TUDCA would not 
inhibit JNK phosphorylation at the 30 minute time point, which we thought would be 
associated with JNK activation that occurs downstream of IL-1R1 and TNF-R1 signaling 
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(Figure 1), but that TUDCA would inhibit JNK phosphorylation 24 hours after the 
addition of cytokines, which we thought would be associated with the induction of ER 
stress and IRE1 activity (Figure 4). Surprisingly, pre-treatment with TUDCA inhibited 
JNK phosphorylation at 30 minutes and 24 hours following stimulation with IL-1β, TNF-α, 
and IFN-γ (Figure 38), suggesting that TUDCA may inhibit HSP90 release in response 
to cytokine stress by inhibiting JNK phosphorylation at both early and late time points. 
Furthermore, pharmacological inhibition and siRNA-mediated knockdown of JNK 
inhibited HSP90 release in response to cytokine stress (Figure 39, 42). These results 
confirm that HSP90 release in response to pro-inflammatory cytokine stimulation was 
mediated, at least in part, by JNK activity in beta cells. However, whether or not JNK is 
activated downstream of IRE1 in response to cytokine stress is still unknown. The fact 
that pre-treatment with TUDCA can inhibit JNK phosphorylation in response to cytokine 
stress does suggest JNK activation and HSP90 release may occur downstream of UPR 
activation.  
However, signaling through IL-1R1 and TNF-R1, the receptors for IL-1β and 
TNF-α, respectively, can also activate JNK activity (Figure 1). Signaling through these 
receptors can also activate other MAPK signal transducers, including p38. However, pre-
treatment of βLox5 cells with SB202190, a pharmacological inhibitor of p38, did not 
inhibit HSP90 release in response to 24 hour stimulation with pro-inflammatory cytokines 
(Figure 40). Furthermore, pre-treatment with TUDCA did not affect p38 phosphorylation 
in response to 30 minute or 24 hour stimulation with IL-1β, TNF-α, and IFN-γ, although 
p38 phosphorylation was not sustained 24 hours after treatment as was JNK 
phosphorylation (Figure 41). Together, these results suggest HSP90 was not released 
in response to activation of p38 MAPK. 
Stimulation with pro-inflammatory cytokines has been shown to deplete ER 
calcium stores in pancreatic beta cells (105). As discussed previously, the concentration 
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of ER Ca2+ is critical for maintaining proper chaperone function and protein folding in the 
ER; thus, depletion of ER Ca2+ results in ER stress and induction of the UPR (29). A 
potential future experiment would be to determine the kinetics of ER Ca2+ depletion in 
response to cytokine stress in βLox5 cells and primary islets. If cytokines are able to 
deplete ER Ca2+ and induce ER stress within 30 minutes, this result would perhaps 
explain why TUDCA was able to inhibit JNK phosphorylation following 30 minutes of 
cytokine stimulation. One could speculate that such a rapid depletion of ER Ca2+ stores 
may promote an alternative, or non-canonical, activation of the UPR, perhaps mediated 
by JNK (Figure 56) (24).  
Severe or prolonged UPR activation is known to favor apoptosis over cell 
survival. Some have postulated that differential activation of IRE1, PERK, and ATF6 may 
determine whether or not a cell undergoes apoptosis in response to ER stress. For 
example, reduced XBP1 splicing via IRE1 endonuclease activity, which promotes 
survival, in favor of JNK activation via IRE1 kinase activity may promote apoptosis in the 
face of severe or prolonged ER stress (106). In the case of prolonged ER stress, CHOP 
is known to play an important role in ER-stress induced apoptosis (107). However, 
cytokine-mediated apoptosis in the rat beta cell line INS-1E was found to occur 
independently of the PERK-ATF4-CHOP axis of the UPR (108). Thus, stimulation with 
high concentrations of pro-inflammatory cytokines may promote a rapid depletion of ER 
Ca2+ levels that induces an acute ER stress that favors IRE1-JNK-mediated apoptosis, 
rather than upregulation of canonical UPR mediators and cell survival (Figure 56). 
Another piece of evidence that supports this assertion is that stimulation of βLox5 cells 
with thapsigargin, which did induce expression of canonical UPR markers (Figure 14, 
29), did not induce JNK phosphorylation (Figure 43). 
Hence our current hypothesis is that pancreatic beta cells release HSP90 in 
response to an acute ER stress that favors JNK activation downstream of IRE1. 
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However, exactly how JNK activation promotes HSP90 release is still unclear at present. 
HSP90 release may be associated with the induction of autophagy or apoptosis, both of 
which occur downstream of JNK activation in the UPR (24). Alternatively, JNK activation 
may promote the upregulation of genes involved in unconventional pathways of protein 
secretion.   
However, as mentioned previously, more experiments are needed to determine 
whether JNK activation occurs downstream of IRE1 activity in response to cytokine 
stimulation. To our knowledge, there is no pharmacological agent or mutation known to 
inhibit IRE1 kinase activity and subsequent JNK phosphorylation (107). Pre-treatment of 
βLox5 cells with the IRE1 endonuclease inhibitor 4μ8c increased the levels of HSP90 
released in response to 24 hour stimulation with IL-1β, TNF-α, and IFN-γ. These results 
further suggest that canonical UPR signaling through the IRE1-XBP1s pathway does not 
promote HSP90 release, but rather, inhibiting IRE1 endonuclease activity with 4μ8c may 
have shifted downstream signaling in favor of IRE1-mediated JNK activation, thus 
increasing HSP90 release in response to cytokine stress. Future studies will be 
conducted to determine the effect of siRNA-mediated knockdown of ERN1, which 
encodes IRE1, on cytokine-induced JNK phosphorylation and HSP90 release from 
pancreatic beta cells. 
Another piece of evidence that suggests pro-inflammatory cytokine stimulation 
promotes a non-canonical activation of the UPR in pancreatic beta cells is that pre-
treatment with TUDCA, which alleviates ER stress, inhibited the upregulation of the 
interferon stimulated genes ISG15 and IFI27 (Figure 35). These results suggest 
transcription of these interferon stimulated genes is, at least in part, mediated by ER 
stress. Indeed several studies have established links between ER stress and 
subsequent activation of inflammatory pathways via the UPR (Figure 56) (23; 104). 
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However, how transcription of these genes is upregulated in response to stimulation with 
IL-1β, TNF-α, and IFN-γ (Figure 35-36) is presently unknown. 
Alternatively, TUDCA may have had off target effects on beta cells, rather than 
specifically inhibiting of ER stress. For example, TUDCA may have blocked upregulation 
of ISG15 and IFI27 by interfering with STAT1 activation. Furthermore, TUDCA may have 
inhibited JNK phosphorylation independently of UPR activation and IRE1 activity. Future 
studies are needed to determine what other effects TUDCA may have on pancreatic 
beta cells. 
One major drawback of using any pharmacological inhibitor is that these drugs 
may produce off-target effects within cells. Thus, HSP90 release may have increased 
further in response to cytokine stimulation with the addition of chetomin, 4μ8C, and 
SB202190 (Figures 25, 37, and 40) due to an association of these drugs with off-target 
proteins, rather than HIF-1α, IRE1, and p38, respectively. Future experiments in which 
these proteins are knocked down or overexpressed could be used to confirm the results 
obtained with these and other pharmacological inhibitors used in the present study.  
Overall, results of these experiments have shown that HSP90 is released by 
human pancreatic beta cells in response to stimulation with a combination of IL-1β, TNF-
α, and IFN-γ, as well as PIC, an agonist of TLR3, but not in response to thapsigargin, 
high glucose, or LPS, an agonist of TLR4. The chemical chaperone TUDCA was able to 
inhibit HSP90 release in response to stimulation with pro-inflammatory cytokines and 
PIC, suggesting HSP90 release was, at least in part, associated with ER stress. TUDCA 
also inhibited JNK phosphorylation in response to stimulation with pro-inflammatory 
cytokines. Both pharmacological inhibition and siRNA-mediated knockdown of JNK also 
inhibited HSP90 release in response to pro-inflammatory cytokine stimulation, 
suggesting HSP90 is also released in response to JNK activation in these cells (Figure 
57). Our current hypothesis posits that JNK is activated downstream of a non-canonical 
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activation of the UPR sensor IRE1. More experiments are needed to determine whether 
PIC stimulation induces HSP90 release via a similar mechanism.  
Thus, these experiments have provided a link between HSP90 release and a 
stress response known to induce apoptosis in pancreatic beta cells. Therefore, these 
results suggest HSP90 may be released from pancreatic beta cells during beta cell 
stress and latent TIDM in vivo and thus may serve as a biological marker of this pre-
clinical phase of disease. 
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VI. Pros and Cons of Using HSP90 as a Biomarker of Latent TIDM 
 One potential drawback of using serum HSP90 as a biomarker of pre-clinical 
TIDM is that it may not be a specific biomarker of beta cell stress, as this protein is 
expressed by all cell types. Elevated serum HSP90 may therefore represent a general 
indicator of cell stress, including malignant transformations associated with cancer. 
However, HSP90 is a highly abundant protein and can constitute up to one to two 
percent of the total protein level in cells. Thus, if a protein were to be detected in the 
serum as a marker of beta cell stress and death, HSP90 would likely be more readily 
detectable than GAD or some other beta cell-specific protein whose expression is much 
lower. Thus, HSP90 would likely be a good candidate for use in a TIDM biomarker panel 
with other markers that may be more difficult to detect but more beta cell-specific, such 
as proinsulin to C-peptide ratios. 
VII. Biological Function of Extracellular HSP90 in the Context of TIDM 
Our results here have shown that HSP90 can be released from pancreatic beta 
cells in response to stress responses known to be associated with latent TIDM in vivo. 
However, the biological function of extracellular HSP90 during beta cell stress and latent 
TIDM is unknown.  
As discussed previously, nearly 30 years ago, HSPs purified from cancer cells 
were found to elicit immunity to tumors, and this immunogenicity was found to result 
from the non-covalent association of HSPs with tumor-specific antigens. These HSP-
antigen complexes could be taken up by APCs through association with the HSP 
receptor CD91. This receptor-mediated uptake of HSP-antigen complexes both 
promoted antigen processing within the APCs and increased presentation of tumor-
associated antigens to T cells in the context of MHC molecules (42).  
More recently, association of HSP90 with antigen has been shown to enhance 
both MHC-I and MHC-II presentation to T cells by promoting antigen uptake through 
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scavenger receptor expressed by endothelial cells (SREC-I) (109; 110). SREC-I is a 
common HSP receptor that is expressed on the surface of dendritic cells that avidly 
binds HSP70, HSP90, GRP94, HSP110, and GRP170 with or without associated 
antigens (111). Moreover, studies from our lab were the first to demonstrate that HSP90 
can associate with the TIDM autoantigen GAD and enhance its presentation (43); 
however, whether or not HSP90 can enhance autoantigen presentation and the 
development of TIDM in vivo remains unknown, but may represent an interesting avenue 
of future research. 
Furthermore, our studies here suggest exosome secretion by pancreatic beta 
cells is increased with pro-inflammatory cytokine stimulation (Figure 9), and unpublished 
studies from Baekkeskov and colleagues have demonstrated similar findings. Exosomes 
are known to play important roles in intercellular communication and biological signaling 
(52). Interestingly, exosomes isolated from insulinoma cells have been shown to contain 
TIDM-associated autoantigens and to trigger autoimmunity in NOD mice (112). 
However, whether or not exosome-associated HSP90 can promote antigen presentation 
and autoimmunity in the context of TIDM remains unclear, but may represent another 
potential avenue of future research.  
In the context of cancer, extracellular HSP90 has been shown to activate MMP-2, 
thus promoting tumor cell invasiveness (58). Interestingly, urine and plasma levels of 
MMP-2 were found to be elevated in patients with TIDM in studies from two independent 
groups (113; 114). However, one can only speculate the combined role of HSP90 and 
MMP-2 in the context of TIDM. Together, these proteins could promote immune cell 
infiltration (extravasation), islet remodeling, or immune cell exit from the islets 
(intravasation) (57). Future studies looking into these mechanisms would certainly merit 
investigation. 
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VIII. HSP90 Chaperone Function in Vivo in the Context of TIDM 
 Despite the fact that we have shown HSP90 is released by pancreatic beta cells 
in response to pro-inflammatory cytokine and PIC stimulation, the in vivo function of this 
protein in the context of disease progression is still unknown. Thus, to answer this 
question, we treated female NOD mice with the HSP90 inhibitor 17-DMAG and 
monitored the progression of TIDM over the course of eighteen weeks. Although 
treatment with 17-DMAG has previously shown beneficial effects in a number of 
autoimmune disease models (36; 37; 41), here 17-DMAG treatment had no effect on the 
incidence of TIDM in NOD mice (Figure 54). Furthermore, 17-DMAG treatment did not 
affect serum HSP90 levels in these animals. Although serum HSP90 levels increased as 
mice aged, both PBS- and 17-DMAG-treated animals exhibited similar levels of serum 
HSP90 throughout the course of the study (Figure 46). This result may reflect the islet 
stress detected in mice treated with 17-DMAG and may suggest HSP90 ATPase 
function is not required for its secretion. 
 Results of qRT-PCR experiments measuring Hspa1b expression levels indicated 
that some animals, although not the majority, may not have responded well to 17-DMAG 
treatment (Figure 45 A). However, 17-DMAG-treated mice that progressed to TIDM lost 
more weight than PBS-treated mice and 17-DMAG-treated mice that did not develop 
diabetes (Figure 49), suggesting 17-DMAG-treated diabetic mice may have been getting 
sicker than the other groups of mice. In the future, control CD1 mice could be treated 
with 17-DMAG to confirm that this effect was specific to diabetic mice. 
Furthermore, islet cells from 17-DMAG-treated mice showed higher expression 
levels of stress-associated genes encoding insulin (Figure 50), ER stress markers 
(Figure 51), heat shock proteins (Figure 52), and autophagy proteins (Figure 53), 
suggesting pancreatic beta cell stress may have been more severe in 17-DMAG-treated 
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mice. Together, these results suggest HSP90 inhibition may have adverse effects on 
beta cell stress, dysfunction, and death in vivo during latent TIDM.  
However, 17-DMAG treatment may have had adverse effects on other systems 
or cell types in the mouse rather than just the pancreatic islet cells alone. This assertion 
is supported by the fact that 17-DMAG-treated diabetic mice lost more weight than PBS-
treated and 17-DMAG-treated non-diabetic mice. This weight loss could be indicative of 
some form of metabolic stress in these mice. Such metabolic stress could have been 
caused by adverse effects of 17-DMAG on the nervous, digestive, endocrine, hepatic, 
musculoskeletal, or other organ systems. For these reasons, HSP90 inhibition is likely a 
poor candidate for a potential TIDM preventative therapy. 
 Rather, these results suggest promoting HSP90 chaperone activity could be 
beneficial in the context of diabetes. A potential future experiment would be to 
overexpress HSP90 in NOD mice to determine whether or not HSP90 expression is able 
to inhibit the development or severity of TIDM in these animals.  
 We originally hypothesized that HSP90 inhibition with 17-DMAG would inhibit the 
development of TIDM in vivo by attenuating immune responses, as had been shown in 
other models of autoimmune disease (36; 37; 41). The authors of these studies 
proposed several mechanisms by which HSP90 inhibition could potentially attenuate 
autoimmune responses. For example, HSP90 is known to chaperone a number of 
molecules involved in intracellular inflammatory signaling cascades including 
phosphoinositide 3-kinase, mammalian target of rapamycin, and Akt as well as the 
transcription factor NF-κB. Thus, HSP90 inhibition may prevent signaling through these 
molecules during immune cell activation (36; 41). 
Furthermore, HSP90 chaperone activity is required for activation of the non-
receptor tyrosine kinase Lck following stimulation of the T cell receptor. Therefore, 
HSP90 inhibition may block T cell receptor signaling and subsequent T cell proliferation 
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(36; 41). Finally, inhibition of HSP90 is known to increase HSP70 expression through 
activation of the transcription factor HSF1. For this reason, HSP70 expression is 
commonly used as a marker for effective HSP90 inhibition. Interestingly, HSP70 has 
also been shown to have a negative feedback effect on NF-κB signaling; therefore, 
HSP90 inhibition may indirectly attenuate NF-κB-mediated inflammatory responses (36; 
37; 41). 
All of these proposed effects are mediated by inhibition of intracellular HSP90 
within immune cells. However in TIDM, beta cell stress and death, particularly ER stress, 
is known to precede the development of disease in NOD mice (64). In the present study, 
HSP90 inhibition appeared to exacerbate beta cell stress responses, and these effects 
may have outweighed any immunomodulatory effects in the context of this particular 
disease model. Treatment with 17-DMAG may have exacerbated beta cell stress 
responses by inhibiting the ER chaperone GRP94, the ER-resident isoform of HSP90. 
Thus, treatment with 17-DMAG may have exacerbated ER stress responses in NOD 
mice. This conclusion is supported by increased expression of Ddit3 (CHOP), Hspa5 
(BiP), and Hsp90b1 (GRP94) in the islet cells of 17-DMAG-treated mice (Figure 51). An 
alternative approach to try in the future may be to use a drug that does not inhibit 
GRP94, such as TAS-166, a selective inhibitor of cytosolic HSP90α and HSP90β (94). 
Given expression levels of various stress markers were increased with 17-DMAG 
treatment in the present study, one might expect that the incidence of TIDM should have 
been higher in 17-DMAG-treated mice compared to PBS-treated controls. The reason 
increased TIDM incidence was not observed with 17-DMAG treatment in light of these 
results is not clear at present. Treatment with 17-DMAG may possibly have exacerbated 
beta cell stress responses without affecting beta cell death and progression to TIDM. 
Given that studies here have shown HSP90 is released from pancreatic beta 
cells during stress responses known to be associated with latent TIDM, supporting a 
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potential role for this protein as a biomarker of pre-clinical disease, another potential 
future approach would be to inhibit extracellular HSP90, but not intracellular, during the 
development of TIDM in vivo.  
In the context of cancer, blocking extracellular HSP90 with antibodies or cell-
impermeable inhibitors was shown to block cancer cell motility and invasion in vitro as 
well as tumor metastasis in vivo (56; 57). Extracellular HSP90 stimulation of cell 
migration in this context occurs through its interaction with CD91, and this property is 
independent of its ability to bind and hydrolyze ATP (56).  This fact is not surprising, 
given concentrations of ATP outside the cell are quite low relative to concentrations 
inside the cell. In the context of TIDM, the function of extracellular HSP90 likely also 
does not depend on its ability to utilize ATP. Thus in the present study, 17-DMAG may 
not have had a significant effect on extracellular HSP90, as this drug inhibits the ability 
of HSP90 to bind and hydrolyze ATP (89; 90). Inhibition of extracellular HSP90, rather 
than intracellular, may have a different effect on the development of TIDM in vivo as it is 
currently unclear whether or not extracellular HSP90 is a risk factor for TIDM 
development in vivo. 
IX. Conclusion 
 In vitro studies here are the first to show that HSP90 is released from pancreatic 
beta cells in response to specific inflammatory stimuli known to be associated with latent 
TIDM. Mechanistic studies further demonstrated that HSP90 release occurs downstream 
of acute ER stress and JNK activation. Therefore, these studies provide mechanistic 
evidence that pancreatic beta cells can release HSP90 in response to stress, thus 
supporting a role for this protein as a potential biological marker of latent TIDM. In vivo 
studies demonstrated that inhibition of HSP90 chaperone activity does not affect the 
overall incidence of TIDM in NOD mice, but rather exacerbates islet cell stress, 
suggesting inhibitors of HSP90 chaperone activity likely do not represent a viable 
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therapeutic option for the prevention of TIDM. Rather, a better approach may be to 
preserve HSP90 chaperone function in individuals at risk for developing TIDM. 
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ONGOING STUDIES AND FUTURE DIRECTIONS 
I. HSP90 Release in Response to Cytokine Stress 
 Studies here have shown that HSP90 is released from pancreatic beta cells in 
response to stimulation with a combination of pro-inflammatory cytokines that included 
IL-1β, TNF-α, and IFN-γ. HSP90 release was found to occur downstream of non-
canonical ER stress and JNK activation. To further elucidate the molecular pathways 
leading to HSP90 release during cell stress, studies are currently underway to determine 
whether or not JNK activation in response to cytokine stress occurs downstream of IRE1 
activity. Human βLox5 cells will be transfected with siRNA targeting ERN1, which 
encodes IRE1, to knockdown expression of this protein. Transfected cells will be treated 
with pro-inflammatory cytokines, and levels of JNK phosphorylation will be analyzed by 
immunoblotting. Additionally, HSP90 release will be measured by ELISA. These studies 
may reveal a target upstream of JNK which could be disrupted to modulate beta cell 
stress. 
 A role for IRE1 and JNK in non-canonical UPR activation will then be confirmed 
by monitoring expression levels of ATF3, XBP1s, NOS2, IL6, ISG15, and IFI27 by qRT-
PCR in cytokine-treated βLox5 cells treated with siRNA targeting JNK or IRE1. These 
experiments will determine whether or not knockdown of these UPR signaling 
components affects expression levels of these genes in a manner similar to TUDCA, 
thus confirming a role for this ER stress pathway in regulating beta cell responses to pro-
inflammatory cytokines. 
 Given that experiments with beta cell lines may not always accurately 
recapitulate what occurs in primary cells, ideally, experiments performed here examining 
the effects of TUDCA, JNK inhibition, and siRNA-mediated knockdown of JNK and IRE1 
on HSP90 release, cell signaling, and gene expression in response to stimulation with 
IL-1β, TNF-α, and IFN-γ should also be performed with primary human cadaveric islet 
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cells. These experiments would confirm the results obtained here with human beta cell 
lines, thus ensuring the biological and translational significance of this mechanistic 
pathway (59). 
II. Mechanism of HSP90 Release 
 Studies here have demonstrated that HSP90 released from beta cells in 
response to cytokine stress is mostly soluble and not associated with exosomes. 
Furthermore, soluble HSP90 was released prior to detection of significant levels of cell 
death, as measured by LDH assay, suggesting HSP90 may be released by a specific 
secretory mechanism. One study recently showed that HSP70 is secreted from tumor 
cells by a mechanism independent of de novo HSP70 synthesis and cell death, similarly 
to what was observed here with HSP90 (100).  
In this study, ammonium chloride, which inhibits lysosome function by raising 
lysosomal pH, inhibited HSP70 release from prostate carcinoma cell lines in response to 
heat shock. Furthermore, HSP70 secretion from these cells correlated with the 
appearance of the lysosomal marker LAMP-1 on the cell surface. Thus, these authors 
proposed that HSP70 was secreted from endolysosomal compartments (100). Studies 
with ammonium chloride in βLox5 cells will be performed to determine whether or not 
HSP90 release in response to cytokine stress occurs via a similar mechanism. 
Additionally, surface levels of LAMP-1 will be examined by flow cytometry. 
III. HSP90 Release in Response to PIC 
 Thus far, studies here have shown HSP90 is released from pancreatic beta cell 
lines in response to stimulation of TLR3 with PIC. Pre-treatment with TUDCA for 6 hours 
partially inhibited HSP90 release in response to PIC stimulation, suggesting that HSP90 
release in response to PIC was mediated, at least in part by ER stress, as was observed 
with pro-inflammatory cytokine stimulation. Based on these results, we hypothesize that 
HSP90 is released in response to JNK activity downstream of UPR activation with PIC 
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stimulation, as was observed with pro-inflammatory cytokine stress. Similar studies that 
were performed with cytokine treatment are needed to confirm whether or not HSP90 
release in response to PIC occurs via this same mechanism. The effect of TUDCA on 
JNK phosphorylation in response to PIC stimulation will be examined by immunoblotting 
in βLox5 cells. Similarly, HSP90 release in response to PIC treatment will be measured 
by ELISA with pharmacological inhibition and siRNA-mediated knockdown of JNK. As 
with cytokine treatment, results obtained with PIC treatment of βLox5 cells should also 
be confirmed with primary human cadaveric islet cells. 
IV. HSP90 as a Biomarker of TIDM in Vivo 
 Previous studies from our lab have shown that serum levels of HSP90 are 
elevated in newly diagnosed patients with TIDM (31). Our studies here helped confirm 
that this protein may be able to serve as a biological marker of latent TIDM by 
demonstrating that HSP90 is released by pancreatic beta cells in response to stress 
stimuli known to be associated with latent TIDM. 
 More in vivo studies are needed, however, to confirm that HSP90 can function as 
a biomarker of latent TIDM. Currently, serum is being collected from NOD mice as well 
as control CD1 mice over time for HSP90 ELISA as the NOD mice progress toward 
TIDM. Results of these experiments will determine whether or not HSP90 levels are 
increased in the serum of animals that develop TIDM, similarly to what was observed in 
humans (31). Islet cell HSP90 levels will also be examined in pancreatic sections from 
these animals by immunohistochemistry staining. These experiments will help confirm 
that HSP90 is being released from islet cells over time as the NOD mice progress 
toward TIDM. 
 If serum HSP90 levels are found to be increased in NOD mice that develop 
diabetes compared to non-diabetic CD1 controls, we next would like to examine the 
effect of blocking diabetes development in NOD mice with TUDCA on serum HSP90 
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levels. Treatment with TUDCA was previously shown to inhibit the development of TIDM 
in NOD mice (82). If preventing TIDM in NOD mice with TUDCA was shown to lower 
serum HSP90 levels, these results would help confirm that this protein can serve as a 
biomarker for latent TIDM in mice. 
 If true, these results will next need to be confirmed in human subjects. Currently, 
clinical trials are underway to test the effects of TUDCA treatment on TIDM development 
in patients with new onset TIDM. We would like to obtain serum samples from these 
patients in order to determine the effects that TUDCA treatment has on serum HSP90 
levels in human subjects in order to confirm that HSP90 can function as a biomarker of 
latent TIDM. If true, serum HSP90 levels could be measured in the clinic to identify 
individual patients at risk for progressing to TIDM, and treatments aimed at preventing 
this disease could be more appropriately administered. 
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